

Curriculum Vitae



First Name: Alireza
Last Name: Khosravi Farsani
Date of Birth: 21.03.1967
Sex: Male
Marital Status: Married
Nationality: Iranian
Religion: Islam

Office:

Office Address: Hypertension Research Center, Cardiovascular Research Institute,
Shahid Rahmani Alley, Moshtagh 3rd Street, Isfahan, Iran.

P.O Box: 81465-1148, Isfahan, Iran.
Office Phone: +98 31 36115217 -36115216
Office Fax: +98 31 36115217
E-mail: alirezakhosravif@gmail.com alirezakhosravi@med.mui.ac.ir

Department:

- Isfahan University of Medical Sciences, School of Medicine, Department of Cardiology
- Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences

Language Skills: Farsi, English

Education

- Professor of Cardiology
- Doctor of medicine (M.D), Isfahan University of medical sciences, Iran. (1985-1992)
Theses Title: determination of prevalence of rheumatic fever in Iranian Population.

- Cardiologist, Department of cardiology, Isfahan University of medical sciences. Isfahan, Iran. (1995-1999).
Theses Title: Validity determination of ST depression during recovery period of exercise test for diagnosis of CAD.
- Fellowship of Interventional Cardiology. Isfahan University of medical sciences. Isfahan, Iran. (2007-2009).
- Different professional educational courses in different techniques in coronary, structural, peripheral and other vascular intervention from Italy, Belgium, Germany, Frances.

Employment

- Isfahan University of Medical Sciences, Faculty of Medicine, Department of Interventional Cardiology, Isfahan, IRAN.
 - ✓ Type of employment: Permanent employment.

Specific Duties and Responsibilities:

- Head of Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences. (2021- continues)
- Head of Hypertension Research center, Cardiovascular Research Institute, WHO Collaborating Center, Isfahan University of Medical Sciences, Isfahan, Iran. (2011-2013, 2016- continues)
- Head of Angiography ward of the Isfahan Shahid Chamran hospital. (2020- continues)
- Responsible of the Working Group on Cardiovascular Diseases, Isfahan University of Medical Sciences. (2021- continues)
- Deputy of Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences. (2020- 2021)
- Research Assistant of Isfahan Cardiovascular research institute. (2020-2021)
- Head of Interventional Cardiology field, Department of Cardiology, Medical school, Isfahan university of medical sciences (2019- continues)
- Head of the Cardiovascular Diseases Working Group. (2017- continues)
- Deputy Head of Angiography ward of the Isfahan Shahid Chamran hospital. (2016-2020)
- Educational Assistant of Isfahan Cardiovascular research institute. (2016 – continues)
- Deputy Head of Interventional Cardiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. (2016- 2019)
- Deputy Head of Interventional Cardiology field, Department of Cardiology, Isfahan university of medical sciences (2016- April 2019)
- Consultant to the head of the Cardiovascular Research Institute, Isfahan, Iran (2018- 2019)
- Head of Interventional Cardiology Research center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran (2013-2016)
- Head of the CCU ward of Isfahan Shahid Chamran hospital (2015 - 2017)
- Head of Heart Clinic of Isfahan Shahid Chamran hospital (2015 – 2018)
- Research Assistant of Department of Cardiology, Medical school, Isfahan university of medical sciences. (2012-2016)

- Head of the cardiology ward of Al-Zahra hospital. (2012-2013)
- Section editor in Interventional Cardiology in Arya Scientific Journal. (2013-continues)
- Scientific secretary of the Blood Pressure Working Group (2015- continues)
- Responsible of the research and educational council of the Iranian Cardiovascular Research Network (2015- continues)
- Head of clinical research unit in Isfahan Cardiovascular Research Center. (2004-2006)
- Head of organizing and programming the intervention conference in Chamran hospital (May 2007).
- Deputy of science committee of national program (IHHP). (2000-2007).
- Head of physician's educational programs in Isfahan Cardiovascular Research Center. (2004)
- Director of Executive, Administrative and Financial Affairs of Isfahan Cardiovascular Research Center. (2004-2006)
- Organizer of training seminars on secondary prevention in cardiovascular disease for physicians in collaboration with WHO and Isfahan Cardiovascular Research Center.

Work Experience (Training Course):

- **More than 20 years' experience in field of cardiology, coronary and non-coronary interventions with treated thousands of patients**
- Coronary Intervention (20 years).
- Structural and peripheral vascular intervention (15 years).
- Participating in the German Heart Center, worked with Cardiac Team and participated in structural heart cases. August 30-31, 2018, Munich. Germany.
- Participating in the Edwards SAPIEN 3 THV Fundamentals Training. September 4-5, 2018, Edwards EMEAC Headquarters-Nyon, Switzerland.
- Participating in learning Expert Techniques in Complex PCI Conduct.16th and 17th of April, Clinique Pasteur, Toulouse, France, 2018.
- Participating in the TTM Skill Training held at Charity Hospital, Berlin, Germany on November 22-23, 2016.
- Participating in International Cardiology RX for change Curriculum: a clinical training in evidence-based treatments for tobacco use.22 Oct 2014, Isfahan, Iran.
- Participating in the fellow in vascular intervention Leuven belgium2005 and 2009
- Participating in the workshop of developed clinical trial in medical research 2003
- Participating in the training workshop on the method of international classification of diseases ICD 10-1999.
- Participating in the workshop on Methods of Writing and Presenting Medical Articles, 1999.

Membership:

- Member of the university committee for the health promotion in mother and newborn. (2023-2025)

- Member of Research council of Pediatric Cardiovascular Research Center. (2021- Continues)
- Secretary / Member of the Isfahan University of medical sciences ICD Committee. (2021- Continues)
- Member of the Heart Team of Isfahan Shahid Chamran hospital (2020- Continues)
- Member of the Patient and Family Education Working Group (2020- Continues)
- Member of the Committee on Economics of Treatment, Medicine and Medical Equipment (2020- Continues)
- Member of Education Coordination Council of department of cardiology (2020- Continues)
- Member of Emergency Committee, Patient Assignment (Bed Management) / Triage. (2020- Continues)
- Member/Expert of the Disease Registration Committee and Health Consequences (2019- Continues)
- Member of the Expert Panel on Cohort Design 2. (2019-continues)
- Member of the Medical Committee of Isfahan Shahid Chamran hospital.
- Member of the examiners group of the specialized board in the field of cardiovascular diseases in Iran. (2019- Continues)
- Member of the examining board and Regional evaluation of Cardiovascular Disease. (2018-2019)
- Member of the University Committee for the Prevention and Control of Non- Communicable Diseases. (2017- continues)
- Member of the Strategic and Policy Council of Isfahan Cardiovascular Institute (2016- continues)
- Member of Research methods committee of Isfahan Cardiovascular Research Center.
- Member of Iranian Heart foundation and Iranian Heart friends.
- Member of the Strategic Council of the Cardiology Research Network. (2011- continues)
- Member of Research council of cardiovascular research Institute. (2013-continues)
- Member of Research council of Isfahan cardiovascular research center (2009- Continues)
- Member of Research council of Hypertension research center. (2011-continues)
- Head of Research council of Hypertension research center. (2011-continues)
- Full time Faculty member of Hypertension research center. (2011-continues)
- Member of Research council of Interventional Cardiology research center. (2013- continues)
- Member of Research council of school of medicine, Isfahan University of Medical Sciences. (2013-2015)
- Member of public council of group PhD by research of Isfahan University of Medical Sciences. (2014 – continues)
- Member of the council of the scientific Arya Atherosclerosis journal. (2013-2014)
- Member of technical committee of Strategic Plan for Prevention and Control of Cardiovascular Diseases comprehensive map of the province's health. (2013- continues)

- Member of the Committee on the Treatment, Medicine and Medical Equipment of the Shahid Chamran Heart Center (2016- continues)
- Member of the Public Health Clinical Committee (2015- continues)
- Member of the research and educational council of the Iranian Cardiovascular Research Network (2015 – continues)
- Member of the Board of Contracts for Promotion-Certified Cardiovascular Diseases.
- Member of publish committee of School of Medicine.
- Member of essential medical training programs in sections apprenticeship and heart. (2009)
- Member organizations multicenter research databases. (2006)
- Committee member financial evaluation of research projects Isfahan Cardiovascular Research Center.
- Member of editorial board and consultants' team of Research in medical science Journal (from 2008)

Published Articles:

International:

1. **Khosravi A** , Eghbali M , Najafian J , Bahonar A , Taheri M, Khosravi M , Nejati M , Behjati M*.Prediction of blood pressure based on anthropometric measurements in adolescents. *Acta Cardiologica*. 2023 Oct 31;1-7. doi: 10.1080/00015385.2023.2256180. Online ahead of print.
2. Dadaei Z, Bagheriya M, Sadeghi O, **Khosravi A**, Shirani Sh, Askari Gh*. Dietary inflammatory index in relation to severe coronary artery disease in Iranian adults. 2023 Sep; 29:10:1226380.
3. NCD Risk Factor Collaboration (NCD-RisC), **Khosravi A**. Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c. *Nature Medicine*. 2023; 29(11): 2885–2901.
4. Mansouri MH, Mansouri P* , Sadeghi M, Hashemi M , **Khosravi A**, Behjati M ,J Shahabi , Mansouri A, Zavar R , Amirpour A, Sanei H, Sarrafzadegan N. Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial). *Clinical Cardiology*. 2023 Sep 18. doi: 10.1002/clc.24158. Online ahead of print.
5. Mansouri A, **Khosravi A**, Mehrabani-Zeinabad K, Kopec J A, Adawi K I I, Lui M, Abdul Rahim H F, Anwar W, Fadhil I, Sulaiman K, Bazargani N, Saade G, Farhan H A, AlMahmeed W, S Bokhari S, Hassen N, Alandejani A, Shirani Sh, Abdin A, Manla Y, Johnson C, Stark B, Roth Gr A, Mokdad A H, Shariful Islam Sheikh M, Sarrafzadegan N*. Trends in the burden and determinants of hypertensive heart disease in the Eastern Mediterranean region, 1990-2019: an analysis of the Global Burden of Disease Study 2019. *EClinicalMedicine*. 2023 Jun. 7(60):102034.
6. NCD Risk Factor Collaboration (NCD-RisC), **Khosravi A**. Diminishing benefits of urban living for children and adolescents' growth and development. *Nature*. 2023; 615(7954): 874–883.

7. Babahajiani M, Zarepur E, **Khosravi A**, Mohammadifard N, Noohi F, Alikhasi H, Nasirian Sh, Moezi Bady A, Janjani P, Solati K, Lotfizadeh M, Ghaffari S, Javanmardi E, Salari A, Gholipour M, Dehghani M, Cheraghi M, Assareh A, Haybar H, Namayandeh M, Madadi R, Kojuri J, Mansourian M*, Sarrafzadegan N. Ethnic differences in the lifestyle behaviors and premature coronary artery disease: a multi-center study. *BMC Cardiovascular Disorders*. 2023 Mar 29;23(1):170.
8. Karimi R, Zarepur E, **Khosravi A**, Mohammadifard N, Nouhi F, Alikhasi H, Nasirian Sh, Sadeghi M, Roohafza H, Moezi Bady A, Janjani P, Solati K, Lotfizadeh M, Ghaffari S, Javanmardi E, Gholipour M, Dehghani M, Cheraghi M, Assareh A, Haybar H, Namayandeh M, Madadi R, Kojuri J, Mansourian M*, Sarrafzadegan N. Ethnicity based differences in statin use and hypercholesterolemia control among patients with premature coronary artery disease- results of I-PAD study. *Int J Cardiol Cardiovasc Risk Prev*. 2023 Mar; 16: 200168.
9. Sayedain Sayed M A, Bahrani S, Mansouri A, Najafian J, Behjati M, Shirani Sh, B Amra, Emami Ardestani M, Khosravi M, **Khosravi A** *. Determination of the Incidence of Cardiovascular Composite Events in Patients with Obstructive Sleep Apnea: A 3-year follow-up Study. *ARYA Atherosclerosis*. 2023 Feb;19(2):53-60.
10. Eghbali M, Akbari M, Seify K, Fakhrolmobasher M, Heidarpour M, Roohafza H, Afzali M, Mostafavi-Esfahani F, Karimian P, Sepehr A, Shafie D*, **Khosravi A**. Evaluation of Psychological Distress, Self-Care, and Medication Adherence in Association with Hypertension Control. *International journal of hypertension*. Volume 2022 | Article ID 7802792
11. Sarrafzadegan N, Bagherikholenjani F*, Noohi F, Alikhasi H, Mohammadifard N, Ghaffari S, Adel M, Assareh A, Zibaee Nezhad M, Tabandeh M, Farshidi H, **Khosravi A**, Nematipour E, Kermani-Alghoraishi M, Hassannejad R, Sadeghi M, Najafian J, Shafie D, Shabestari M, Mansouri A, Roohafza H, Shahidi Sh, Yarmohammadian M, Moeeni M. Priority setting in cardiovascular research in Iran using standard indigenous methods. *Journal of Research in Medical Sciences*. 2022 Dec 23;27:91. doi: 10.4103/jrms.jrms_343_22.
12. **Khosravi A**, Eghbal A, Kermani-Alghoraishi M, Behjati M, Shahabi J, Mansouri A *. Short and one-year outcome of endovascular aortic repair (EVAR) for abdominal aortic aneurysms (AAAs). *ARYA Atherosclerosis*. September and October 2022; Volume 18:1-7.
13. Haghigatdoost F, Atefi M, Mohammadifard N *, Daryabeygi-Khotbehsara R, **Khosravi A**, Mansourian M. The relationship between ultraprocessed food consumption and obesity indicators in Iranian adults. *Nutrition, Metabolism & Cardiovascular Diseases*. 2022;32(9):2074-2085.
14. Gholami A, Ghanbari A, Rezaei Sh, Baradaran H, Khatibzadeh S, Parsaeian M, Hariri M, Zamaninour N, Sheidaei A, Abdollahi M, Mirmiran P, Ghayour-Mobarhan M, Ostovar A, Mohammadifard N, **Khosravi A**, Namayandeh M, Farzadfar F *. National and sub-national trends of salt intake in Iranians from 2000 to 2016: a systematic analysis. *Archives of Public Health*. 2022;13;80(1):120
15. Mansouri M, Esmaeili F*, **Khosravi A**, Mansouri P, Mirmohammadsadeghi M, Dehghan H, Jameie M, Amirpour A, Zavar R. Comparison of Pulmonary Emboli Management Between Pulmonary Emboli Response Team and the Conventional Method: The First Study from Iran. *Critical Pathways in Cardiology*. 2022;21(2):61-66.

16. Roghani-Dehkordi F, Farazandeh F, Kermani-Alghoraishi M*, **Khosravi A**. Comparison of pain severity, satisfaction, and complications of proximal and distal forearm anesthesia in patients undergoing trans-palmar coronary angiography. Anatolian journal of cardiology. 2022; 26(1): 37-42.
17. Mohammadifard N, Grau N, **Khosravi A**, Esmaillzadeh A , Feizi A , Abdollahi Z , Sarrafzadegan N*.Validation and reproducibility of a semiqualitative food frequency questionnaire for assessment of sodium intake in Iranian population. Nutrition Journal. 2022;4;21(1):1-12.
18. Rahimlou M, Grau N, Banaie –Jahromi N, Taheri M, **Khosravi A**, Mavrommatis Y, Mohammadifard N*. Association of adherence to the dietary approach to stop hypertension and Mediterranean diets with blood pressure in a non-hypertensive population: Results from Isfahan Salt Study (ISS). Nutrition, Metabolism & Cardiovascular Diseases. 2022 Jan;32(1):109-116.
19. Kermani-Alghoraishi M, Pourbehi A,Kafi F*, **Khosravi A****. Coronavirus disease 2019 (COVID-19) and severe pericardial effusion: from pathogenesis to management: A Case Report Based Systematic Review. Current problems in cardiology.2022;47(2):1-18.
20. **Khosravi A**, Behjati M, Mansouri A, Jozan M, Mohammadifard N, Taheri M, Khodarahmi S, Ansari R, Mansouri MH,Mansouri P*, Sarrafzadegan N .Evaluation of correlation between digital vs. mercury sphygmomanometer in a middle-income country: The role of socio-economic situation. Clinical and Experimental Hypertension.2022;44(2):113-118.
21. Javanbakht S, Eghbali M, Bolourinejad P, Sherafat A, **Khosravi A**, Hashemi M*, Sarrafzadegan N. Maternal or paternal history: Which one plays more important role in developing hypertension? ARYA Atherosclerosis.2022;17(2): Article number 2263.
22. Eghbali M, Mansouri A*, Nouri F, Mohammadifard N, Gharipour M, Jozan M, Rabiei K, Azarm T, **Khosravi A**. Morning Exercise at School and Sedentary Activities Are Important Determinants for Hypertension in Adolescents. International Journal of Preventive Medicine.2021; Oct 19;12:131. doi: 10.4103/ijpvm.IJPVM_41_19.
23. Sadeghi-Gandomani H, Habibi Z, Eghbali-Babadi M*, **Khosravi A**. Impact of Telenursing on Blood Pressure and Body Mass Index of People with Prehypertension: A Randomized Controlled Clinical Trial. Iranian Journal of Nursing and Midwifery Research.2021;26(6):544-549.
24. Shemirani H, Zavar R, **Khosravi A**, Tavakoli M*. The Comparing of Short Clinical Cardiovascular Outcomes with Wraparound and Nonwraparound Left Anterior Descending Artery in Patients with Anterior ST-Segment Elevation Myocardial Infarction. Heart Views.2021;22(3):184-188.
25. Soltani S, Saraf-Bank S, Basirat R, Salehi-Abargouei A, Mohammadifard N, Sadeghi M, **Khosravi A**, Fadhil I, Puska P, Sarrafzadegan N*. Community-based cardiovascular disease prevention programmes and cardiovascular risk factors: a systematic review and meta-analysis. Public Health. 2021 Nov; 200:59-70
26. Eghbali-Babadi M, **Khosravi A**, Feizi A, Alikhasi H, Kheirollahi N*, Sarrafzadegan N. Prevalence of pre-hypertension and hypertension, awareness, treatment, and control of hypertension, and cardiovascular risk factors in postmenopausal women. ARYA Atherosclerosis.2021;17:1-9.

27. **Khosravi A**, Alavi M*, Eghbali Babadi M, Shahriari M, Molavi R, Mahmoodi A, Archibald M. Physicians' Perspectives of the Factors Influential in Implementing National Clinical Guidelines for Hypertension in Iran: A Qualitative Study. Preventive Care in Nursing and Midwifery Journal.2021; 11(4): 55-62.
28. NCD Risk Factor Collaboration (NCD-RisC), **Khosravi A**. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 2021 Sep 11;398(10304):957-980.
29. Emami M, Shafie D, Vakhshoori M, Eghbali-Babadi M, Ahmadipour E, **Khosravi A***. Corrigendum to "Evaluation of the Efficiency of Indirect Blood Pressure Measurement Methods in Comparison to Intra-Arterial Reading among Iranian Individuals" [Inter Cardiovasc Res J. 2020, 14 (3); e103852]. International Cardiovascular Research Journal.2021;15(2): :84-84. icrj.114521
30. Kermani-Alghoraishi M, Shirvani E, **Khosravi A***, Roghani-Dehkordi F, Shemirani H, Farshidi H, Assareh A, Moezi A, Sarrafzadegan N. Survey of Coronary Catheterization Laboratory Activity in Iran During the Coronavirus Disease-2019 Pandemic. ARYA Atherosclerosis.2021;17(1):1-7.
31. Vaseghi G, Taheri M, Heshmat K, Rayati M, Zarfeshani S, Pourmoghaddas A, **Khosravi A**, Zarepour E, Keshavarzrad P, Arabi S, Azizi M, Haghjooy Javanmard Sh, Najafian J, Sarrafzadegan N*. Familial Hypercholesterolemia (FH) in Iran: Findings from the Four-Year FH Registry. Journal of Lipids. Volume 2021, Article ID 9913969
32. NCD Risk Factor Collaboration (NCD-RisC), **Khosravi A**. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. eLife. Volume 10, March 2021, Article number e60060.
33. Mohammadifard N, Mahdavi A, **Khosravi A**, Esmaillzadeh A, Feizi A, Saarfzadegan N*. Salt intake and its sources in children, adolescents and adults in Isfahan, Islamic Republic of Iran. Eastern Mediterranean Health Journal. 2021 Mar 23;27(3):279-286
34. Sadeghipour P, Talasaz A, Eslami V, Gerayeli B, Vojdanparast M, Sedaghat M, Fakhr Moosavi A, Alipour Parsa S, Aminian B, Firouzi A, Ghafari S, Ghasemi M, Kazemi Saleh D, **Khosravi A**, Kojuri J, Noohi F, Pourhosseini H, Salarifard M, Salehi M, Sezavar H, Shabestari M, Soleimani A, Tabarsi P, Zand Parsa A, Abdi s*. Management of ST-segment-elevation myocardial infarction during the coronavirus disease 2019 (COVID-19) outbreak: Iranian "247" National Committee's position paper on primary percutaneous coronary intervention. Catheterization and cardiovascular interventions. 2021;97(3):346-351.
35. **Khosravi A**, Mansouri A, Shahsanayi F, Paydari N, Heshmat-Ghahdarijani K, Mansourian M, Nouri F, Taheri M, Farshidi H, Kazemi T, Khaledifar A, Assareh A, Behnammoghadam M, Peighambari M, Nematipour E, Sarrafzadegan N*, Noohi F. Rationale and Design of the Persian Cardiovascular Disease Registry (PCVDR): Scale-Up of Persian Registry of Cardiovascular Disease (PROVE). Current Problems in Cardiology. 2021;46(3), Article number 100577
36. Shayganfar A, Moradi M, Moshiri R, **Khosravi A**, Ebrahimian S*. Is High preprocedural Renal Resistive Index Sensitive Enough to Predict Iodine Contrast-Induced Nephropathy in Patients Receiving Intra-Arterial Iodinate Contrast? Current Problems in Diagnostic Radiology. 2021 May;50(3):328-331.

37. Mohammadifard N, Karimi G, **Khosravi A**, Sarrafzadegan N, Jozan M, Zahed P, Haghigatdoost F*. High dietary acid load score is not associated with the risk of metabolic syndrome in Iranian adults. International Journal for Vitamin and Nutrition Research. 2021;91(1-2):152-163.
38. Arsang-Jang S, Mansourian M, Mohammadifard N, **Khosravi A**, Oveis-Gharan S, Nouri F, Sarrafzadegan N*. Temporal trend analysis of stroke and salt intake: a 15-year population-based study. Nutritional Neuroscience. 2021;24(5):384-394.
39. Zarepur E, Mohammadifard N, Mansourian M, Roohafza H, Sadeghi M, **Khosravi A**, Nouri F, Azdaki N, Salehi N, Lotfizadeh M, Sarrafzadegan N*. Rationale, design, and preliminary results of the Iran-premature coronary artery disease study (I-PAD): A multi-center case-control study of different Iranian ethnicities. ARYA Atherosclerosis.2020;16(6):295-300.
40. **Khosravi A**, Rajabi H, Vakhshoori M, Rabiei K, Hosseini M, Mansouri A, F Roghani-Dehkordi, Najafian J, Rahimi M, Jafari-Koshki T, Sadeghian B, Shishehforoush M, Lahijanzadeh A, Taheri M, Sarrafzadegan N*. Association between ambient fine particulate matter with blood pressure levels among Iranian individuals admitted for cardiac and respiratory diseases: Data from CAPACITY study. ARYA Atherosclerosis.2020;16(4):178-184.
41. Heshmat-Ghahdarijani K, Jangjoo Sh, Amirpour A, Najafian J, **Khosravi A**, Heidarpour M, Hekmat M, Shafie D*. Endothelial dysfunction in patients with lone atrial fibrillation. ARYA Atherosclerosis.2020;16(6):1-6.
42. Roghani-Dehkordi F, Riazi A, Shafie D, **Khosravi A**, Sadeghi M, Vakhshoori M, Massoudi S, Kermani-Alghoraishi M*. Trans-snuff box approach as a new access site for coronary angiography and angioplasty versus trans-radial approach in terms of feasibility, safety, and complications. ARYA Atherosclerosis.2020;16(6):1-6.
43. NCD Risk Factor Collaboration (NCD-RisC), **Khosravi A**. Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. Lancet 2020; 396(10261): 1511–24.
44. Seify K, Vakhshoori M, Eghbali-Babadi M, Heidarpour M, **Khosravi A**, Feizi A, N Sarrafzadegan, Shafie D*. Antihypertensive drugs adherence and its association with blood pressure control status. Current Medicine Research and Practice.2020;10(2):49-53.
45. Emami M, Shafie D, Vakhshoori M, Eghbali-Babadi M, Ahmadipour E, **Khosravi A***. Evaluation of the efficiency of indirect blood pressure measurement methods in comparison to intra-arterial reading among Iranian individuals. International Cardiovascular Research Journal.2020;14(3):108-113.
46. **Khosravi A**, Vakhshoori M, Sharif V, Roghani-Dehkordi F, Najafian J, Mansouri A*. Comparison of survival rate and complications of percutaneous coronary intervention, coronary artery bypass graft, and medical treatment in patients with left main and/or three vessel diseases. ARYA Atherosclerosis.2020;16(2):85-93
47. Mohammadifard N, Haghigatdoost F*, Nouri F, **Khosravi A**, Sarrafzadegan N. Is urinary sodium excretion related to anthropometric indicators of adiposity in adults? Journal of Research in Medical Sciences.2020;25(1):1-9.
48. **Khosravi A**, Kermani M*, Pourmoghadas M. Ascending Aorta Thrombosis: A Rare Cause of Simultaneous Acute Myocardial Infarction and Upper Limb Ischemia. Acta Cardiol Sinica.2020 Jul;36(4):382-385.

49. NCD Risk Factor Collaboration (NCD-RisC), **Khosravi A**. Repositioning of the global epicentre of non-optimal cholesterol. *Nature*. 2020 Jun;582(7810):73-77.
50. Jafari F, Shahriari M*, Sabouhi F, **Khosravi A**, Eghbali-Babadi M. The effect of a life style management educational program on blood pressure, heart rate, and body mass index in patients with hypertension. *ARYA Atherosclerosis*. 2020; 16 (1):7-15.
51. Mohammadi-Dolatabadi A, Vakhshoori M, Eghbali-Babadi M, Heidarpour M, Shafie D*, Garakyaraghi M, **Khosravi A**. Comparison of multiple blood pressure frequency methods with optimum blood pressure measurement among Iranian individuals. *Journal of Research in Medical Sciences*. 2020;25(1):1-6.
52. Mohammadifard N, Marateb H*, Mansourian M, **Khosravi A**, Abdollahi Z, Campbell R, Webster J, Petersen K, Sarrafzadegan N*. Can methods based on spot urine samples be used to estimate average population 24 h sodium excretion? Results from the Isfahan Salt Study. *Public Health Nutrition*. 2020 Feb;23(2):202-213.
53. Shirvani E, Sadeghi M, Hosseini M*, **Khosravi A**, Rabiei K, Rahimi M, Jafari-Koshki T, Shishehforoush M, Lahijanzadeh A, Moazam E, Mohebi M, Sarrafzadegan N. Fine Particle Air Pollution (PM 2.5) and Cardiovascular Hospitalization in Isfahan in 2012: CAPACITY Study. *Iranian Heart Journal*; 2020;21(1):75-81.
54. Roghani-Dehkordi F, Hosseinzadeh H, KermaniAlghoraishi M, **Khosravi A**, Vakhshoori M, Sadeghi M, Danesh M, Sadeghi N, Sahfie D*. The transulnar approach in the patients with ipsilateral radial artery occlusion. *Arya Atherosclerosis*. 2020;16(1):33-38.
55. Mirniam AA, Habibi Z, **Khosravi A**, Sadeghi M, Eghbali-Babadi M*. A clinical trial on the effect of a multifaceted intervention on blood pressure control and medication adherence in patients with uncontrolled hypertension. *Arya Atherosclerosis*. 2019;15(6):267-274.
56. Eghbali-Babadi M, Feizi A, **Khosravi A***, Nouri F, Taheri M, Sarrafzadegan N. Development and evaluation of the psychometric properties of a hypertension self-care questionnaire. *Arya Atherosclerosis*. 2019;15(5):241-249.
57. Mohammadifard N, **Khosravi A***, Salas-Salvadó J, Becerra-Tomás N, Nouri F, Abdollahi Z, Jozan M, Bahonar A, Sarrafzadegan N. Trend of salt intake measured by 24-hour urine collection samples among Iranian adult's population between 1998 and 2013: The Isfahan salt study. *Nutrition, Metabolism & Cardiovascular Diseases*. 2019;29(12):1323-1329.
58. NCD Risk Factor Collaboration (NCD-RisC), **Khosravi A**. Rising rural body-mass index is the main driver of the global obesity epidemic in adults. *Nature*. 2019; 569(7755):260-264.
59. Shemirani H, **Khosravi A**, Eghbal A*, Amirpour A, Roghani F, Hashemi-Jazi M, Pourmoghaddas A, Heidari R, Sajjadieh A, Sadeghi N, Sanei H. Comparing efficacy of receiving different dosages of eptifibatide in bleeding after percutaneous coronary intervention in patients with myocardial infarction. *Arya Atherosclerosis*. 2019;15(4):185-191.
60. Vaseghi G, Arabi S, Haghjooy-Javanmard S, Sabri M, Sadeghi M, **Khosravi A**, Zarfeshani S, Sarrafzadegan N*. CASCADE screening and registry of familial hypercholesterolemia in Iran: Rationale and design. *Arya Atherosclerosis*. 2019;15(2):53-58.
61. **Khosravi A**, Mohammadifard N*, Gharipour M, Abdollahi Z, Nouri F, Feizi A, Jozan M, Sarrafzadegan N. Low correlation between morning spot and 24-hour urine samples for estimating sodium intake in an Iranian population: Isfahan Salt Study. *Int J Vitam Nutr Res*. 2019;89(3-4):185-191.

62. Baktashian M, Saffar Soflaei S, Kosari N, Salehi M, **Khosravi A**, Ahmadinejad M, Moohebati M, Ebrahimi M, Rahmani F, Khameneh-Bagheri R, Ahmadi M, Sadabadi F, Tayefi M, Bazhdanzadeh S, Ferns GA, Hashemi SM, Pasdar A, Ghavour-Mobarhan M*. Association of high level of Hs-CRP with in-stent restenosis: A case-control study. *Cardiovasc Revasc Med.* 2019;20(7):583-587.
63. Roghani-Dehkordi F, Mansouri R*, **Khosravi A**, Mahaki B, Akbarzadeh M, Kermani-Alghoraishi M. Transulnar versus transradial approach for coronary angiography and angioplasty: Considering their complications. *Arya Atherosclerosis.* 2018 May; 14(3):128-131.
64. **Khosravi A**, Behjati M*, Dianatkhan M, Noori F, Sarrafzadegan N, Nejati M. The Effect of Parental Medical History on the Prevalence of Cerebrovascular Diseases in Their Children in an Iranian Population. *Basic Clin Neurosci.* 2018;9(5):367-372.
65. Eghbali M, Feizi A, **Khosravi A***, Sarrafzadegan N. The Effect of Training on Knowledge, Attitude, and Practice in Patients with Hypertension; the Application of the Expanded Chronic Care Model: A Clinical Trial Study. *Iranian Red Crescent Medical Journal.* May 2018;20(5).
66. **Khosravi A**, Pourmoghadas M, Movahed M.R*. Successful percutaneous closure of a large symptomatic AV fistula using an amplatzer occluder device. *Cardiovascular Revascularization Medicine.* 2018; 19(8):23-24.
67. **Khosravi A**, Ziae Bideh F*, Roghani F, Saadatnia M, Khorvash F, Nejati M, Khoshpour N, Behjati M. Carotid arterial stent implantation follow-up and results in 50 patients: preliminary report. *Electronic Physician.* 2018; 10(2):6400-6405.
68. **khosravi A**, Mirdamadi A, Movahed MR*. Successful Retrieval of Embolized Atrial Septal Defect Occluder and Patent Foramen Ovale Closure Device Using Novel Coronary Wire Trap Technique. *Catheterization and cardiovascular interventions.* 2018; 92(1):189-192.
69. Eghbali M, **Khosravi A**, Feizi A, Mansouri A, Mahaki B, Sarrafzadegan N. Prevalence, awareness, treatment, control, and risk factors of hypertension among adults: a cross-sectional study in Iran. *Epidemiology and health.* 2018.18 May; 40. e2018020
70. Eghbali- Babadi M, **Khosravi A***, Feizi A, Sarrafzadegan N. Design and implementation of a combined observational and interventional study: Trends of prevalence, awareness, treatment and control hypertension and the effect of expanded chronic care model on control, treatment and self-care. *Arya Atherosclerosis.* 2017; 13(5):211-220.
71. Bahonar A, **Khosravi A**, Khorvash F, Maracy M, Saadatnia M*.Seasonal and Monthly variation in stroke and its subtypes-10 Year Hospital-Based Study. *Mater Sociomed.* 2017; 29(2):119-123.
72. Bahonar A, **Khosravi A**, Khorvash F, Maracy M, Oveisgharan S, Mohammadifard N, Saadatnia M*, Nouri F, Sarrafzadegan N. Ten-year trend in stroke incidence and its subtypes in Isfahan, Iran during 2003-2013. *Iran J Neurol.* 2017. 7; 16(4):201-209.
73. Haidari A, Moeini M*, **Khosravi A**. The Impact of Peer Support Program on Adherence to the Treatment Regimen in Patients with Hypertension: A Randomized Clinical Trial Study. *Iran J Nurs Midwifery Res.* 2017;22(6):427-430.
74. **Khosravi A**, Rajabi D*, Pourmoghadas M, Roohi A, Esmaili M. The role of manual thrombectomy in cardiovascular outcome among patients with total cutoff vessel myocardial infarction undergoing primary percutaneous coronary intervention. *Arya Atherosclerosis.* 2017; 13(2):66-72.

75. **Khosravi A**, Andalib E, Khalidifar A, Hajizadeh M, Nejati M, Behjati M*. Pulmonary thromboembolism presenting with recurrent bradycardia and hypotension. *Tanaffos*. 2017; 16(3):248-250.
76. Mohammadifard N, Khaledifar A*, **khosravi A**, Nouri F, Pourmoghadas A, Feizi A, Esmailzadeh A, Sarrafzadegan N. Dietary sodium and potassium intake and their association with blood pressure in a non-hypertensive Iranian adult population: Isfahan salt study. *Nutrition & Dietetics*. 2017; 74(3):275-282.
77. Givi M, Sarrafzadegan N*, Garakyaragh, Yadegarfar G, Sadeghi M, **Khosravi A**, Azhari A.H, Samienasab M.R, Shafie D, Saadatnia M, Roohafza H, Paydari N, Soleimani A, Hosseinzadeh M, Ahmadi S.A, Dehghani L, Najafian J, Andalib E, Shahabi J, Sabri M.R. Persian registry of cardiovascular disease (Prove): Design and methodology. *Arya Atherosclerosis*. 2017; 13(5):236-244.
78. Roghani F, Tajik MN*, **Khosravi A**. Compare Complication of Classic versus Patent Hemostasis in Transradial Coronary Angiography. *Adv Biomed Res*. 2017; 26;6:159.
79. **khosravi A**, M Sadeghi, M Barghikar*. Which Components of Metabolic Syndrome have a Greater Effect on Mortality, CVA and Myocardial Infarction, Hyperglycemia, High Blood Pressure or Both? *Advanced Biomedical Research*. 2017; 6(1):121.
80. Golpour-Hamedani S, Mohammadifard N, **Khosravi A**, Feizi A, Safavi M*. Dietary approaches to stop hypertension diet and obesity: A cross-sectional study of Iranian children and adolescents. *ARYA Atherosclerosis Journal*. 2017; 13(1):7-13.
81. Rafie N, Mohammadifard N, **Khosravi A**, Feizi A, Safavi M*. Relationship of sodium intake with obesity among Iranian children and adolescents. *ARYA Atherosclerosis Journal*. 2017; 13(1):1-6.
82. Bahonar A, Saadtnia F, Khosravi F, Maracy M, Khosravi A*. Carotenoids as potential antioxidant agents in stroke prevention: A systematic review. *International Journal of Preventive Medicine*. 2017; 8(70): 6-12.
83. Sarrafzadegan N, Gharipour M*, Sadeghi M, Nezafati P, Talaie M, Oveisgharan S, Nouri F, **khosravi A**. Metabolic Syndrome and the risk of Ischemic Stroke. *J Stroke Cerebrovasc Dis*, Feb 2017; 26(2):286-294.
84. **Khosravi A**, Gharipour M, Nezafati P*, Khosravi Z, Sadeghi M, Khaledifar A, Taheri M, Golshahi J, Sarrafzadegan N. Pre-hypertension, pre-diabetes or both: which is best at predicting cardiovascular events in the long term? *Journal of Human Hypertension*, 2017; 31(6):382-387.
85. Jafari F, MS, Shahriari M*, Sabouhi F, MS; **Khosravi A**, Eghbali Babadi M. Effects of a Lifestyle Modification Program on Knowledge, Attitude and Practice of Hypertensive Patients with Angioplasty: A Randomized Controlled Clinical Trial. *International journal of community based nursing and midwifery*. 2016; 4(4):286-296.
86. Shahrani A, Daryabeigi R*, Shahriari M, **khosravi A**. Effect of continuous care model on lifestyle modification in patients with hypertension: Randomized clinical trial study. *International journal of medical research & health science*, 2016; 5(7):231-239.
87. Mohammadifard N, **khosravi A**, Esmailzadeh A, Feizi A, Abdollahi Z, Salehi F, Sarrafzadegan N*. Rationale, design and Initial Findings: Validation of simplified tools for Assessment of sodium intake in Iranian population. *Archives of Iranian Medicine*, September 2016; 19(9):652-658.

88. Mohammadifard N, **Khosravi A**, Esmailzadeh A, Feizi A, Abdollahi Z, Salehi F, **Sarrafzadegan N***.Validation of simplified tools for assessment of sodium intake in Iranian population:Rationale,Design and initial findings. Archives of Iranian Medicine,September 2016;19(9):652-658.
89. **Khosravi A**,Gharipour M,Behjati M*,Sadeghi M, Nezafati P,Talaie M,Shirani S, jozan M. Paternal or maternal history of hypertension is more important in increasing the risk of hypertension innofspring? Acta Biomed, 2016; sep 13; 87(2):161-7.
90. haidari A, Moeini M*, **Khosravi A**. Effect of the peer supportive program on blood pressure changes in patients affected with hypertension: A randomized controlled trial. International Journal of Medical Research & Health Sciences, 2016, 5, 7S:98-102.
91. Pourmoghaddas M, **Khosravi A**, Akhbari M*, Akbari M,Pourbehi M,Ziae F,Salehizadeh L,Sistan N,Esmaeili M,Bidram P. One year follow-up effect of renal sympathetic denervation in patients with resistant hypertension. ARYA Atherosclerosis Journal, 2016; 12(2):109-113.
92. Abdolazimi M, **Khosravi A**,Sadeghi M,Mohammadian-Hafshejani A, Sarrafzadegan N,Salehiniya H,Golshahi J*. Predictive factors of short-term survival from acute myocardial infarction in early and late patients in Isfahan and Najafabad, Iran ARYA Atherosclerosis Journal,2016;12(2):1-9.
93. **Khosravi A**, Ahmadzadeh S, Gharipour M, Golshahi J*, Sadeghi M, Jozan M, Sarrafzadegan N. Is there any relationship between different phenotypes of metabolic syndrome and cardiovascular mortality rate? Advanced Biomedical Research,2016.
94. **Khosravi A**, Gharipour A, Gharipour M*, Khosravi M, Andalib E, Shirani S, Mirmohammadsedeghi M. Advanced method used for hypertension's risk factors stratification: support vector machines and gravitational search algorithm. ARYA Atherosclerosis Journal, 2015,11(6):349-356.
95. **Khosravi A**, Pourbehi M*, Pourmoghaddas M,Ostovar A,Akhbari M, Ziae-Bideh F,Golshahi J,Shirani S. Evaluating the impact of fractional flow reserve-guided percutaneous coronary intervention in intermediate coronary artery lesions on the mode of treatment and their outcomes: An Iranian experience. ARYA Atherosclerosis Journal, 2015; 11(4):220-227.
96. Etemadifar S*, Bahrami M,Shahriari M, **Khosravi A**. Family Caregivers' Experiences of Caring for Patients With Heart Failure: A Descriptive, Exploratory Qualitative Study. Journal of Nursing Research, 2015:23(2):153-161.
97. Gharipour M, Sarrafzadegan N*, Sadeghi M, **Khosravi A**, Hoseini M, Khosravi-Boroujeni H, Khaledifar A. The metabolic syndrome and associated lifestyle factors among the Iranian population. Advanced Biomedical Research, 2015; 4(1):1-6.
98. Khaledifar A, Gharipour M, Bahonar A, Sarrafzadegan N, **Khosravi A***. Association between dietary salt intake and reservation of renal function in patients with mild hypertension. ARYA Atherosclerosis Journal, 2015; 11(Special Issue 1):1-5.
99. Gharipour M, Bahonar A*, Sarrafzadegan N, **Khosravi A**, Khaledifar A. Are there any differences in education levels and changes of cardiovascular risk factors among urban and rural population: Isfahan Healthy Heart Program? J Educ Health Promot. 2015; 4:1-7.
100. Bahrami M, Etemadifar Sh*, Shahriari M, **Khosravi A**. Informational needs and related problems of family caregivers of heart failure patients: A qualitatine study. Journal of Education and Health Promotion, 2014; Nov (3):1-6.

101. Etemadifar S, Bahrami M*, Shahriari M, Khosravi A. The effectiveness of a supportive educative group intervention on family caregiver burden of patients with heart failure. Iranian Journal of Nursing and Midwifery Research, 2014; 19(3):217-223.
102. **Khosravi A**, Gharipour M, Abdar M*, Saadatnia M, Roghani F, Shirani S, Khaledifar A. Perspective on the hospital incidence rate of deep venous coagulopathy: Clinical and biochemical diagnostic markers. Advanced Biomedical Research, 2014; 3(1):1-6.
103. **Khosravi A**, Pourheidar B*, Roohafza H, Moezzi M, Mousavi M, Hajiannejad A, Bidram p, Gharipour M, Shirani S, Golshahi J, Boshtam M, Sarrafzadegan N. Evaluating factors associated with uncontrolled hypertension: Isfahan cohort study, Iran. ARYA Atherosclerosis Journal, 2014; 10(6):311-318.
104. **Khosravi A**, Behjati M*, Nilforoush P, Saieedi M, Balouchi A. A case of Marfan's syndrome with multi-level aortic dissections. ARYA Atherosclerosis Journal, 2014; 10(6):334-338.
105. Ashrafi F, Darakhshan A*, Nematolahi P, **Khosravi A**. complete heart block in a patient with POEMS syndrome: A case report. ARYA Atherosclerosis Journal, 2014; 10(5):276-279.
106. Bahrami M, Etemadifar S*, Shahriari M, **Khosravi A**. Caregiver burden among Iranian heart failure family caregivers: A descriptive, exploratory, qualitative study. Iranian Journal of Nursing and Midwifery Research, 2014; 19(1):56-63.
107. Hemmati R, Gharipour M*, **Khosravi A**, Jozan M. A Cost-Benefit and Accurate Method for Assessing Microalbuminuria: Single versus Frequent Urine Analysis. Hindawi Publishing Corporation, International Journal of Hypertension, Volume 2013, Article ID 752903, 4 pages.
108. Khaledifar A, Gharipour M, Bahonar A, Sarrafzadegan N, **Khosravi A***. Association between Salt Intake and Albuminuria in Normotensive and Hypertensive Individuals Hindawi Publishing Corporation, International Journal of Hypertension, Volume 2013, Article ID 523682, 4 pages.
109. Sadria S, Pourmoghaddas M, Hadizadeh M, Maghamimehr A, Esmaeeli M, Amirpour A, **Khosravi A***. Factors affecting outcome of primary percutaneous coronary intervention for acute myocardial infarction. ARYA Atherosclerosis Journal, 2013; 9(4):241-246.
110. **Khosravi A**, Noohi F, Andalib E, Sadeghiyan S, Peighambari M, Sarrafzadegan N* and Working Group. Management of High Blood Pressure: The First Iranian High Blood Pressure Guideline (Summary), Iranian Heart Journal 2013; 13 (1):27-35.
111. Gharipour M*, Ramezani M, Sadeghi M, **Khosravi A**, Masjedi M, Khosravi-Boroujeni H, Rafieian-kopaei M, Sarrafzadegan N. Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program. Journal of Research in Medical Sciences, 2013; 18:467-72.
112. Haghigatdoost F, Sarrafzadegan N, **Khosravi A**, Noori F, Boshtam M, Mohammadifard N, Abdollahi Z, Azadbakht L*. Is the association between salt intake and blood pressure mediated by body mass index and central adiposity?. Archives of Iranian medicine. 2013; 16(3):167.
113. Najafian J*, Toghianifar N, **Khosravi A**. Exertional abdominal pain as a symptom of secondary pulmonary hypertension in mitral stenosis. Nigerian journal of clinical practice. 2013; 16(1):110.
114. **Khosravi A**, Hoseinabadi M*, Pourmoghadas M, Shirani Sh, Paydari N, Sadeghi M, Kanani S, Jozan M, Khosravi E. Primary percutaneous coronary intervention in the Isfahan province,

- Iran; A situation analysis and needs assessment. ARYA Atherosclerosis Journal, 2013; 9 (1):38-44.
115. Khosravi A, Raoufi A*, Pourmoghadas M, Paydari N, Gharipour M, Namdari M, Khaledifar A, Khosravi M, Bahonar A, Ostovan M, Hasanzadeh M, Sarrafzadegan N. Late clinical events of drug eluting versus bare metal stenting; OPCES' ancillary study. Pak J Med Sci, 2013; 29(1):258-263.
116. Gharipour M, **Khosravi A**, Sadeghi M*, Roohafza H, Hashemi M, Sarrafzadegan N. Socioeconomic characteristic and controlled hypertension: Evidence from Isfahan Healthy Heart Program. ARYA Atherosclerosis journal. 2013; 9(1):77-81.
117. Gharipour M, Kelishadi R, Khosravi A, Shirani Sh, Masjedi M*, Sarrafzadegan N. The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007. Arch Med Sci, 2012; 8(6):1009-1017
118. Noohi F, Sarrafzadegan N, **Khosravi A***, Andalib E. The first Iranian recommendations on prevention, evaluation and management of high blood pressure. ARYA Atherosclerosis Journal, 2012; 8(3):97-118
119. **Khosravi A**, Toghianifar N, Sarrafzadegan N*, Gharipour M, Azadbakht L. Salt intake, obesity, and pre-hypertension among Iranian adults: A cross-sectional study. Pak J Med Sci, 2012; 28(2):297-302
120. **Khosravi A**, Rowzati M, Gharipour M, Gholamali Fesharaki M, Shirani S, Shahrokhi S, Jozan M, Khosravi E, Khosravi Z, Sarrafzadegan N*. Hypertension control in industrial employees: findings from SHIMSCO study. ARYA Atherosclerosis journal 2012; 7(4):191-196.
121. Ansari R*, **Khosravi A**, Bahonar A, Shirani S, Kelishadi R, Khosravi Z. Risk factors of atherosclerosis in male smokers, passive smokers, and hypertensive nonsmokers in central Iran. ARYA Atherosclerosis Journal. 2012; 8(2).
122. **Khosravi A**, Ansari R, Shirani Sh, Baghai A, Sarrafzadegan N*. Causes of failure to control hypertension in people over 65 years of age. ARYA Atherosclerosis Journal, 2012, 7(5):42-46.
123. **Khosravi A**, Kelishadi R, Sarrafzadegan N*, Boshtam M, Nouri F, Zarfeshani S, Esmailzadeh A. Impact of a community-based lifestyle intervention program on blood pressure and salt intake of normotensive adult population in a developing country. J Res Med Sci 2012; 17(3):235-241.
124. Shirani Sh, Samiee Nasab M, Samimi K, Forouzandeh M, **Khosravi A***. Comparison of sensitivity and specificity of cardiac size estimation through plain chest x-ray and two echocardiography. ARYA Atherosclerosis Journal, 2012, 7(5) (Special Issue):1-4.
125. Sabet B, Derakhshan R, Derakhshan F, Kelishadi R, **Khosravi A***. Association of body mass index, waist-to-hip ratio and waist circumference with cardiovascular risk factors: Isfahan Healthy Heart Program. ARYA Atherosclerosis Journal, 2012 (Special Issue); 7(5):47-50.
126. Khosravi-Boroujeni H, Mohammadifard N, Sarrafzadegan NI, Sajjadi F, Maghroun M, Khosravi A, Alikhasi Hn, Rafieian M, Azadbakht L*. Potato consumption and cardiovascular disease risk factors among Iranian population. Int J Fod Sci Nutr, 2012; 63(8):913-20.
127. Khosravi A, Akhavan Tabib A*, Golshadi I, Dana Siadat Z, Bahonar A, Zarfeshani S, Alikhasi H, Rezaei Sh, Nouri F, Hashemi S.M. The Relationship between Weight and CVD Risk Factors in a Sample Population from central Iran (Based on IHHP). ARYA Atherosclerosis J, 2012, 8(2):82-89.

128. Mohammadifard N, Fahimi S, Khosravi A, Pouraram H, Sajedinejad S, Pharoah P, Malekzadeh R, Sarrafzadegan N*. Advocacy Strategies and Action Plans for Reducing Salt Intake in Iran. *Archives of Iranian Medicine*, 2012; 15(5): 320 – 324.
129. Sarrafzadegan N, Gharipour M*, Sadeghi M, Khosravi A, Tavassoli A. Metabolic syndrome in Iranian elderly. *ARYA Atherosclerosis Journal*, 2012; 7(4):157-61.
130. Shemirani H, Khosravi A*, Hemmati R, Gharipour M. Body Mass Index or Microalbuminuria, which one is more important for the prediction and prevention of diastolic dysfunction in Non-diabetic Hypertensive patients. *Int J Prev Med*.2012 Mar; 3(3):211-20.
131. Shemirani H, Hemmati R, Khosravi A, Gharipour M*, M Jozan. Echocardiographic assessment of inappropriate left ventricular mass and left ventricular hypertrophy in patients with diastolic dysfunction. *JRMS*, 2012; 17(2); 133-137.
132. Shirani Sh, Gharipour M, Khosravi A*, Kelishadi R, Habibi H, Abdalvand A Sarrafzadegan N. Gender differences in the Prevalence of hypertension in a representative sample of Iranian population: the Isfahan Healthy Heart Program. *Acta biomed*, 2011;82(3):223-229.
133. Khosravi A, Pourmoghaddas M, F Ziae, Enteshari A, Khaledifar A, Bahonar A*. Does lipoprotein (a)level have a predictive value in restenosis after coronary stenting. *Int J Prev Med* 2011Jul-Sep;2(3):158-163.
134. Tavassoli A, Gharipour M*, Toghianifar N, Sarrafzadegan N, khosravi A, Zolfaghari B, Zarfeshani S. The impact of obesity on hypertension and diabetes control following healthy Lifestyle Intervention Program in a developing country setting. *JRMS* 2011; 16(Special Issue): 368-376.
135. Khosravi A, Pourmoghaddas M*, Asadi K, Abdi A, Gholamrezaei A. Immediate results and six months outcomes after precutaneous coronary intervention in a referral heart center in Isfahan,Iran. *ARYA Atherosclerosis Journal*.2011;7(1).24.
136. Sarrafzadegan N*, Gharipour M, Ramezani M, Rabiei K, Zolfaghari B, Tavassoli A, Boshtam M, Zarfeshani S, Khosravi A, yousefi A. Metabolic syndrome and health-related quality of life in Iranian population. *journal of research in medical science*.2011;16(3):254-261.
137. Gharipour M*, Kelishadi R, Toghianifar N, Tavassoli A, Khosravi A, Sajadi F, Sarrafzadegan N. Socioeconomic Disparities and Smoking Habits in Metabolic Syndrome: Evidence from Isfahan Healthy Heart Program. *Iran Red Crescent Med J*2011; 13(8):537-543.
138. Hemmati R, Gharipour M*, Shemirani H, Khosravi A, Khosravi E. Urine Albumin to Creatinine Ratio and Echocardiographic Left Ventricular Structure and Function in Patients with Essential Hypertension. *Am Heart Hosp J*.2011; 9(2); 90-4.
139. Khosravi A, Pourmoghaddas M, Ostovan M, Kiani Mehr G, Gharipour M, Zakeri H, Soleimani B, Namdari M, Hassanzadeh M, Tavassoli A, Ghaffari S, Khaledifar A, Roghani F, Khosravi M, Sarami S, Kojouri J, Nouri F, Khosravi E, Jozan M, Sarrafzadegan N*. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study. *JRMS* 2011; 16(5): 640-650.
140. Rajabizadeh G, Ramezani M*, Roohafza H, Pourdamghan N, Khosravi A, Rabiei K, Sarrafzadegan N, Toghianifar N, Zarfeshani S. Association between cigarette smoking and socio-demographics, lifestyle and mental health factors in a sampled Iranian population. *Southeast Asian J TropMed Public Health* 2011, 42(4):977-87.

141. Akhlaghi A, Shirani S, Ziae N, Pirhaji O, Yaran M, Shahverdi G, Sarrafzadegan N, Khosravi A*, Khosravi E. Cytochrome p450 2c19 polymorphism in Iranian patient with coronary artery disease. ARYA Atherosclerosis journal 2011, 7(3):106-10.
142. Kelishadi R*, Sarrafzadegan N, Sadri G, Pashmi R, Mohammadifard N, Tavassoli A, Amani A, Rabiei K, Khosravi A, Bahonar A .Short-Term Results of a Community-Based Program on Promoting Healthy Lifestyle for Prevention and Control of Chronic Diseases in a Developing Country Setting: Isfahan Healthy Heart Program. Asia Pac J Public Health. 2011;23(4),518-533.
143. Sarrafzadegan N, Kelishadi R*, Najafian A, Khosravi A, Bahonar A, Asgari S, Sadri G, Amani A, Eshrat B. Anthropometric indices in association with cardio metabolic risk factors: findings of the Isfahan healthy heart program. ARYA Atherosclerosis Journal 2010, 5(4): 152-162
144. Khosravi A,Kiani mehr G,Kelishadi R*,Shirani S,Gharipour M,Tavassoli A,Nouri F, Sarrafzadegan N.The impact of a 6-year comprehensive community trial on the awareness,treatment and control rates of hypertension in Iran:Experiences from the Isfahan healthy heart program.BMC cardiovascular disorders.2010;1-8.
145. Tavassoli A, Gharipour M, Khosravi A*, Kelishadi R, Dana Siadat Z, Bahonar A, Sadri G, Sadeghi M, Rabiei K, Sajadi F, Zarfeshani S, Eshrat B, Shirani S, Sarrafzadegan N. Gender Differences in Obesogenic Behavior, Socioeconomic and Metabolic Factors in a Population-based Sample of Iranians: The IHHP Study, J HEALTH POPUL NUTR 2010 Dec;28(6):602-609.
146. Khosravi A, Ramezani M*,Toghianifar N, Rabiei K, Jahandideh M, Yousofi A. Association between Hypertension and quality of life in a sample of Iranian adults. ACTA Cardiol, Aug2010;65(4);425-430.
147. Sarrafzadegan N*, Kelishadi R, Dana Siadat Z, Esmaillzadeh A, Solhpour A, Shirani S, Naderi G, Asgary S, Sadri G, Khosravi A, Bahonar A. Obesity and cardiometabolic risk factors in a representative population of Iranian adolescents and adults in comparison to a Western population: The Isfahan Healthy Heart Programme. Public Health Nutr. 2010, 13(3), 314–323.
148. Bahonar A*, Khosravi A, Esmaelian H, Babak A, Sarrafzadegan N, Rahmati M, Jamshidi A, Azad M, Daneshvar P. Methods of implementing the operational phases of the health professional's education Project-Isfahan healthy heart program (IHHP-HPEP), ARYA Atherosclerosis Journal 2009, 5(3): 103-107.
149. Beigi A,Sadeghi A.M, Khosravi A,Karami M,Masoudpour H*.Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure.journal of vascular access.2009;10(3).160.
150. Shirani S, Kelishadi R*, Sarrafzadegan N, Khosravi A, Sadri G, Amani A, Heidari S, Ramezani M. Awareness, treatment and control of hypertension, dyslipidemia and diabetes mellitus in an Iranian population: the IHHP study. East Mediterr Health J, Nov-Dec2009, 15(6);1455-63.
151. Khosravi A*, Avesta L, Ramezani M, Bahonar A, Heidari H, Tavassoli A, Sarrafzadegan N. Assessment of relation between microalbuminuria and ischemic electrocardiogram in Iranian general population. ARYA Atherosclerosis journal, spring2009, 5(1):33-38.
152. Khosravi A*, Kelishadi R, Pourmoghaddas M, Shirani S, Asgari S,Khosravi M. Preprocedural C-reactive protein predictive value in angiographic in-stent restenosis after coronary stent placement in patients with stable angina . ARCHIVES OF MEDICAL SCIENCE 2009;5(2):166-171.

153. Beigi A, Khosravi A, Mir-Mohammad Sadeghi A*, Safaei M. Cardiac performance in end stage renal disease diabetic patients with arteriovenous fistula. ARYA Atherosclerosis journal, 2008; 4(1):33-36.
154. Sarrafzadegan N, Rabiei K, Kabir A*, Sadeghi M, Khosravi A, Asgari S, Taghipour HR, Roohafza H. Gender differences in risk factors and outcomes after cardiac rehabilitation. Acta Cardiol. 2008 Dec; 63(6):763-70.
155. Shahrokhi S, Kelishadi R*, Sarrafzadegan N, Khosravi A, Roohafza H, Pooya A, Mollabashi R. Evaluation of the Quit and Win contest for smoking cessation in the Islamic Republic of Iran. Eastern Mediterranean Health J. Dec 2008, 14(6):1270-9.
156. Khosravi A*, Movahedi B, Pourmoghaddas M, Ansari R. Paraxonas (PON) activity in Less than 40 years old non diabetic Patients with and without significant coronary artery disease. ARYA Journal, 2008, 4(2):53-58.
157. Sarrafzadegan, N, Rabiei, K, Kabir A*, Khosravi A, et al. Changes In Lipid Profile Of Patients Referred To A Cardiac Rehabilitation Program Source: European Journal Of Cardiovascular Prevention & Rehabilitation 2008; 15(4):467-472.
158. Kelishadi R*, Sharifi M, Khosravi A, Adeli Kh. Relationship between C-reactive protein and atherosclerotic risk factors and oxidative stress markers among young person's 10-18 years old Source: CLINICAL CHEMISTRY 2007;53(3):456-464.
159. Kelishadi R*, Mokhtari M, Tavasoli A, Khosravi A, Ahangar-Nazari I, Sabet B, Kazemi A, Amini A. Determinants of tobacco use among youths in Isfahan, Iran. Int J Public Health. 2007; 52(3):173-9.
160. Oveisgharan Sh*, Sarrafzadegan N, Shirani S, Hosseini Sh, Hasanzadeh P, Khosravi A. Stroke in Isfahan, Iran: hospital admission and 28-day case fatality rate: Cerebrovascular Diseases 2007: 24(6):495-499.
161. Khosravi A*, Abdi A, Sarrafzadegan N, Ansari R, Kianimehr G, Roghaei F, Siadat Z. The effect of low-dose niacin added to simvastatin on lipoprotein profile. Arya Atherosclerosis spring 2007;3(1):8-13.
162. Shahrokhi S*, Asgari S, Khosravi A, Naderi GH, Taheri M. The effect of nicotine gum on blood pressure and heart rate. ARYA atherosclerosis J, 2006; 1(4) 252-254.
163. Ashtari F, Shayegan-nejad V, Khosravi A, Saberi A*, Niknazar M. The Influence of Chlamydia Pneumoniae Infection On Intima-Media-Thickness (Imt) In Common Carotid Artery. ARYA Atherosclerosis Journal 2006, 2(3): 130-133.
164. Khosravi A*, Shirani SH, Shahrokhi SH, Mohammadifard N, Ansari R. Antihypertensive Drugs Used by Hypertensive Patients in The Provincial Cities of Isfahan, Najafabad and Arak. ARYA Atherosclerosis J 2006; 1(4):275-81.
165. Kelishadi R*, Sadri G, Tavasoli A, Kahbazi M, Roohafza H, Sadeghi M, Khosravi A, Sabet B, Amani A, Ansari R, Alikhasi H. Cumulative prevalence of risk factors for atherosclerotic cardiovascular diseases in Iranian adolescents: IHHP-HHPC. J Pediatr (Rio J). 2005 Nov-Dec; 81(6):447-53.
166. Kelishad R*, hashemipour M, Sadeghi M, Roohafza H.R, Tavasoli A.A, Khosravi A, Ansari R, Ansari Z, Bashardoust N. The impact of familial factors on obesity in Iranian chidren and adolescents. J Ped Neonat, 2005; 2(2): 16-23.

167. Khosravi A*, Pourmoghaddas M, Kelishadi R, Sabet B, Ansari R, Shirani SH, Sarraf zadegan N. Trends in blood pressure level, prevalence of hypertension and its care in Isfahan. MJIRC , 2005, 8(2):62-68.
168. Kelishadi R*, Derakhshan R, Sabet B, Sarrafzadegan N, Kahbazi M, Sadri G.H , Tavasoli A.A, hHeidari A, khosravi A, Amani A, Tolouei HR, Bahonar A, Rezaei Ashtiani AA, Moatarian A. The metabolic syndrome in hypertensive and normotensive subjects: the Isfahan healthy heart program. Annals Acardemy of Medicine, 2005, 34(3):243-9
169. Khosravi A*, Ansari R, Shirani Sh. Causes of uncontrolled blood pressure in the over-65 populations. ARYA Journal 2005, 1(2):101-105.
170. Khosravi A*, Ansari R, Shirani Sh. Blood pressure levels and trends of obesity in hypertensive patients versus health individuals: Isfahan 1991-2001. ARYA Journal 2005; 1(1):19-24
171. Pourmoghaddas M, Khosravi A*, Kelishadi R, Sarrafzadegan N, Shirani S, Ansari R, Sabet B. Trends in Blood PressureLevel, Prevalence and Control of Hypertension in Isfahan, Iran. Iranian Heart Journal 2004; 5(1,2):33-38.
172. Kelishadi R*, Sabet B, Khosravi A. Anticardiolipin antibody adolescents and age of myocardial infarction in parents. Med Sci Monit, 2003;9(12):515-8

National:

173. Shemirani H, Hadi N*, Jafarian R, Sadeghi M, Khosravi A, Mansouri A. The Effect of Hemodialysis of on Serum Troponin I level in Patients with Renal Disease and Normal Left Ventricular Ejection Fraction. Journal of Isfahan Medical School. 2022;39(655):993-998.
174. Ahmadi A, Sabri M, Navabi Z, Eghbali-Babadi M*, Khosravi A, Mohammadifard N. Facilitating and Impeding Factors in Successful Weight Loss among the Adolescents with Overweight and Obesity: A Qualitative Study. Journal of Isfahan Medical School. 2022; 4th Week, September;40(680):539-549.
175. Vakhshoori M, Eghbali-Babadi M, Shafieyoon Sh, Feizi A, Heidarpour M, Shafie D*, Khosravi A, Sarrafzadegan N. The Relation between Blood Pressure and Anthropometric Indices among Iranian Adults. Journal of Isfahan Medical School. 2019;37(513):31-39.
176. Sedghi M, Hashemi S.M, **Khosavi A**, Riaziat A.R, Rezayatmand M.R, Sabetjoo V, Tasdighi H, Baktashian M*. Evaluation of the coronary angiography results in patients referred to cardiac centers in Isfahan City, Iran. Journal of Isfahan Medical School. 2017; 34(417):1-6.
177. Khosravi A, Jozan M, Gharipour M*, Rowzati M, Khosravi E, Sarrafzadegan N. Effect of work place intervention in controlling hypertension. Journal of Birjand University of Medical Sciences (supplementary: cardiovascular). 2013; 19 (6): 10-16.
178. Sotodeh Asl N*, Neshat Dost HT, Kalanteri M, Talebi H, **Khosravi A**. Comparison of the effectiveness of two methods of hope Therapy and Drug therapy on the quality of life in the patients with essential hypertension. Journal of clinical psychology. spring2010; 2(1):27-34.
179. Sotodeh asl N*, Neshat Dost H, Kalanteri M, Talebi H, **A Khosravi**. Comparison of the effectiveness of cognitive behavioral therapy and medication on the quality of life in the patients with essential hypertension. Semnan University of Medical Sciences 2010, 11(4):294-301.

180. Mohajer H, **Khosravi A**, Saadatnia M*, Abdar M, Azarm T. Genetic Thromboembolic Risk Factors Associated with Deep Vein Thrombosis in an Iranian Population. Journal of Isfahan Medical School 2010, 28(114);795-800.
181. **Khosravi A**, Akhavan Tabib A*, Golshadi I, Dana Siadat Z, Bahonar A, Zarfeshani S, Alikhasi H, Rezaei Sh, Nouri F, Hashemi S.M. The Relationship between Weight and CVD Risk Factors in a Sample Population from central part of Iran (Based on IHHP). RJMS. 2010; 17 (72) :31-41
182. Akhavan tabib A*, saeedi .M, Bahonar. A, **khosravi. A**, Dana Siadat. Z, Alikhasi H.the relationship between TG and high waist circumference with cardiovascular risk factor in female area of Iran. Jundishapur Scientific Medical Journal. 2008, 7(2).
183. Roghani F*, **Khosravi A**, A Case report of acute dissection of LM during coronary angioplasty. Shahrekord University of Medical Sciences 2008; 10(1): 89-92.
184. Saijadi F*, Mohammadifard N, **Khosravi A**, et al. Nutritional knowledge, attitude and practice of health professional about cardiovascular disease: results of Isfahan Healthy Heart Program. Birjand University of Medical Sciences 2008; 2 (15): 65-73.
185. Ansari R*, **Khosravi A**, Mokhtari M .Prevalence and cause of smoking in the medicine students. Journal of Semnan University of Medical Sciences.2007 9(1):21-26.
186. Shahrokh Sh*, **Khosravi A**, Asgary S, Javadi H.R. Kap study on smoking in Iranian medical doctor. Qazvin Medical University Journal. 2006; 9(4):47-52).
187. Asgary S*, Naderi GH, Gharipour M, Sabet B, **Khosravi A**, In vitro effect of nicotine and cotinine on the susceptibility of LDL oxidation and hemoglobin glycosylation. The Journal of Qazvin univ of Med Sci. 2005; 9(2): 20-25.
188. **Khosravi A***, Ansari R, Shirani Sh, Baghai A .The Causes of failure to control hypertension in population aged over 65. The Journal of Qazvin univ of Med Sci. 2005, 35summer:8-14.
189. Asgary S*, Gharipour M, Naderi Gh, Sabet B, **Khosravi A**, Hashemi M. Evaluation Of Autoantibody Against Modified Ldl Levels In Patients With Cardiovascular Diseases.Iranian journal of Diabetes and Metabolism.2005;4(2):15-21.
190. **Khosravi A***, Pourmoghaddas M, Sarrafzadegan N, Ansari R, Kelishadi R, Shirani S, Sabet B. Ten yaers trend of hypertension in over 18 years old persons in Isfahan. The journal of Shahrekord University of Medical Sciences.2004;6(4):87-94.
191. Khosravi A, Mohammadifard N, Shahrokh Sh, Shirani Sh, Ansari R. Drugs used in patients with high blood pressure in central areas of Iran. J Isf Med school. 2004; 22(73 &74).
192. Ansari R, **Khosravi A**, Sarrafzadegan N, Kelishadi R, Khosravi E. The Relation of the Blood Pressure Level and Obesity in Hypertensive Patients and Healthy Persons in Isfahan 1370-1380. Yasuj uni Med Sci 2003; 8(2): 1-9.
193. **Khosravi A**, Nasr A. Sabet B. Namazi M. Evaluation of theoretical knowledge and practical skill assessment in nursing staff, interns and residents working in different wards of Alzahra Hospital about cardiopulmonary resuscitation in summer 2003. J Isf Med school (2003) 22(71).
194. **khosravi A***, Mazarei A, Pourmoghaddas M, Ansari R, Shirani Sh. The effect of Iranian and non-Iranian atenolol tablets in hypertensive patients. Shahrekord University of Medical Sciences 2001; 3(1): 47-59.
195. Shirani Sh*, **Khosravi A**, Ansari R, Shahrokh SH, Sajjadi F, Kelishadi R. Effect of one-years intervention on the knowledge and practice of nutrition in the community (public) center area of Iran, IHHP Study. Shahrekord University of Medical Sciences 2001; 3(1): 84-96.

196. Ansari R, **Khosravi A**, Bahonar A, Shirani SH, Kelishadi R. Prevalence of Atherosclerosis risk factors in hypertensive smokers, non-smokers and passive smokers with hypertension in central Iran. Shahrekord medical science university. 2001;3(1): 23-34.
197. Pourmoghaddas M, **Khosravi A**, Jamshidi R. Three years of early experience in coronary angioplasty, early success and the role of atherosclerosis risk factors in it. J Isf Med school 2001;19(63&64).
198. Pourmoghaddas M*, **Khosravi A**, Kia B. Comparison of restenosis in balloon angioplasty patients with and without stent. Shahrekord University of Medical Sciences. 2001;3(2);22-30.
199. Kelishadi R*, Rabiee K, **Khosravi A**, Famori F, Sadeghi M, Roohafza HR, Shirani SH. Assessment of physical activity among adolescent in Isfahan. The Journal of Shahrekord University of Medical Science 2001; 2: 55-62.

Research Studies:

1. The Relationship Between Fermented and Non-Fermented Dairy Products Consumption and Hypertension Among Premature Coronary Artery Disease Patients: Iran-Premature Coronary Artery Disease Study (I-PAD)
2. Evaluation of coronary artery disease severity and lifestyle-related risk factors in patients with premature coronary artery disease in three different ethnicities: A large-scale cross sectional study.
3. Identifying barriers to progress in the implementation of cardiovascular disease prevention and control programs in various fields and providing corrective solution.
4. Two-year trends of changes blood pressure and other risk factors of cardiovascular disease in children and adolescents with essential hypertension in Isfahan.
5. Setting up a prospective cohort study to follow-up and assessment of cardiovascular events incidence in patients with hypertension in hypertension clinic of Isfahan Cardiovascular Research Institute (ICRI).
6. Setting up a registration and follow-up system for hypertensive patients in Isfahan city with the aim of data integration.
7. Assessment of the cardiovascular composite events in Patients with Obstructive Sleep Apnea; A five year follow up.
8. Self-rated health and its determinants in patients with hypertension in Isfahan 2019.
9. Socio-economic inequality in hypertension control in patients with hypertension in Isfahan-2019.
10. Genetic evaluation of exons 21 and 26 of ABCB1 gene and its effect on the pharmacokinetics and pharmacodynamics of rivaroxaban in Iranian population.
11. Clinical and Biochemical Characteristics of Patients with Clinical Diagnosis of Familial Hypercholesterolemia in Isfahan.
12. The Association Between Dietary Inflammatory Index and Vascular Blockage Index, And Vascular Blockage Location Using Angiography Data Among Iranian Adults: a cross-sectional study.
13. Determining the incidence of non-communicable and communicable diseases, recurrence rate, disease consequences, and mortality in a five-year prospective

longitudinal cohort study based on a hospital registry of COVID 19 patients in Isfahan (Defeat COVID 19) Cohort Study.

14. Screening of Hypertension in Adolescents to Achieve a map to the Implementation of a Cohort Study on Adolescents with Hypertension Background in Isfahan Province.
15. Development of national clinical practice guidelines for the Management, Diagnosis and Treatment of Acute Coronary Syndromes.
16. Comparing Effectiveness and Safety of Synchronized Electrical Cardioversion by ZOLL and SAIRAN- Electroshocks in Patients with Atrial Fibrillation: A Non-Inferiority Single Blinded Randomized Clinical Trial.
17. Assessing the Impact of Training general practitioners the latest hypertension international and national Guidelines on Controlling their Under-Treatment Hypertensive Patients.
18. Anti-anginal and anti-ischemic effects of Empagliflozin in diabetic patients with refractory angina.
19. Successful & unsuccessful weight control in adolescents with obesity: Qualitative research in Isfahan.
20. Determining the prevalence of premature coronary heart disease and its risk factors according to different ethnicities and religions in Iran and developing a biobank for epigenetic studies
21. Chronic Ischemic Cardiovascular Disease (CICD) Long-Term Registry.
22. Percutaneous Coronary Intervention's (PCI) Registry in Esfahan Iranian Registry of Percutaneous Coronary Interventions (Pilot).
23. Evaluation of the contributing and inhibitory factors of the implementation of the national guide for prevention, evaluation and treatment of hypertension in the medical team of Isfahan University of Medical Sciences.
24. Evaluation of oxidative stress in restenosis and the role of paraoxonase in progression of the disease.
25. Effect of selenium supplementation on pre inflammatory markers in subjects with mets.
26. Identifying association between IL-10, TNF α , AnxA5 genes polymorphism and plasma inflammatory cytokines concentrations contributing to restenosis after percutaneous coronary intervention.
27. Updating Preparation Iranian Recommendations on Prevention, Evaluation and Management of High Blood Pressure (Guideline).
28. Launching the first medical, research and educational center for high blood pressure in Isfahan.
29. Validation of feed frequency questionnaire to assessment sodium intake and the share of food groups in receiving it in two age groups of adults, children and adolescents in Isfahan.
30. Epidemiologic study of the incidence and case fatality rates of stroke in Isfahan, 2001-2013.
31. Evaluation of the effect of self-care programs and localized treatment strategies on improving blood pressure control in Iran.

32. Preparation of the First Iranian Recommendations on Prevention, Evaluation and Management of High Blood Pressure (Summary)
33. Evaluation of urinary sodium in adult & children in Isfahan urban area.
34. Designing a sensitization model for community and high-risk groups to reducing salt intake in Isfahan.
35. Evaluation of sodium, chlorine and salt amounts in the main food sources of salt in Iranian society.
36. Preparation of the First Iranian Recommendations on Prevention, Evaluation and Management of High Blood Pressure (Guideline).
37. Risk score in patients with diabetic foot ulcers that refer to skin and leishmaniosis research center of Esfahan University of Medical Science.
38. Improving the level of health in high risk and poor control employees (patients with high blood pressure) in Mobarakeh Steel Company (Complementary Plan)
39. Assessment of Incidence of pulmonary hypertension and pulmonary hypertension pressure changes in hemodialysis patients in Alzahra hospital.
40. Assessment of salt intake per day based on the amount of urinary sodium chloride excretion in 24 hours in people older than 18 years of age in Isfahan and Najafabad.
41. Assessment of the effect of treating cardiovascular risk factors on the risk of cardiovascular incidence in hypertensive patients in Isfahan's Folad-Mobarakeh workers.
42. Acute Coronary Events -A Multinational Survey of current managements Strategies
43. Assessment of cardiovascular incidence rate following administration of Osvix compared to Plavix after coronary artery stenting.
44. Comparison effectiveness of Acupuncture and Iranian bupropion in cessation of Smoking short (one month) and long term (12 months) abstinence.
45. International smoking quit competition in 2006 (Quite & Win)
46. Evaluation of national plan of the integrating for control HTN in the rural area of Isfahan.
47. Comparative study of the effect of potassium salt and common salt on the blood pressure status of patients with hypertension
48. The comparison of effect of low dose immediate release nicotinic acid with simvastatin on high level HDL-serum.
49. Comparative Evaluation of Effects of Cardiac Rehabilitation on Morbidity and knowledge -Attitude-Practice (KAP) of Cardiac Patients About Cardiovascular Risk factors in a one Cohort study
50. The Effect of Health courier on Improving the Awareness and Performance of Nursing Staff in Educational and Social Security Hospitals to Prevent and Control Non- Communicable Diseases
51. Evaluation of short-term and long-term heart damage in patients with stroke 40-75 years' old
52. Healthy lifestyle for high-risk people in studying Isfahan healthy heart.
53. International smoking quit competition in 2004. (Quite & Win)
54. Evaluation of metoral effect on 30 days' cardiovascular complications in patients with moderate to high cardiovascular risk who undergo non cardiac surgery

55. Evaluation the relation between insulin resistance and restenosis after PTCA in non-diabetic ischemic patients
56. Evaluation of early and late outcomes in patients with carotid artery disease treated by percutaneous carotid angioplasty and stenting in Isfahan
57. Assessing the effect of educational interventions on the level of awareness of health care personnel regarding the control and treatment of cardiovascular and stroke diseases working in Isfahan, Najafabad and Arak health centers.
58. A comparison of primary coronary angioplasty with streptokinase in acute myocardial infarction.
59. Evaluation of the Comparison of Effectiveness and Side Effects of External Lovastatin and Lovastatin Manufactured by Domestic Pharmaceutical Companies.
60. Prevention of Recurrent MI and stroke.
61. Effect of metabolic syndrome score on atherosclerotic risk profile and coronary artery disease severity via angiography
62. Evaluating the rate of LDL oxide on restenosis after doing angioplasty
63. Evaluation the effect of treatment for chlamydia and helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndrome
64. Evaluation of care and cost of acute stroke in Iran
65. Assessment of myocardial perfusion imaging validity by SPECT method in diagnosis of significant coronary artery stenosis in comparison with "coronary angiography in Isfahan"
66. Effect of metabolic syndrome score on atherosclerotic risk profile and coronary artery disease severity via angiography.
67. Effect of estrogen on Maximal Walk Distance in patient with Intermittent Claudication.
68. Assessment of serum Lp (a) level, fibrinogen, and anti-cardiolipin antibody in patients with recurring stenosis following PTCA.
69. Evaluation of the trend of changes cardiovascular risk factors in people over 35 years old in three central cities of Iran.
70. Evaluation of the level of awareness, performance and belief of general practitioners about the treatment of patients .
71. Evaluation of the effect of nutritional interventions on increasing the awareness, attitude and nutritional performance of people in the community (healthy food project for a healthy society).
72. Evaluation of the effect of hydrochlorothiazide and indapamide, foreign and Iranian ethanol in controlling blood pressure in people aged 25-75 years who refer to the blood pressure clinic of Isfahan Cardiovascular Research Center
73. Health personnel training project in Isfahan, Najafabad, and Arak
74. Healthy life for cardiovascular patients(HLCP)
75. Healthy Life for Cardiovascular Patients Health Personal Education
76. Trend of incidence, prevalence fatality, morbidity and mortality due to myocardial infarction and stroke in rural and urban areas of Isfahan, Najaf- Abad and Arak

Supervised Thesis's:

- 1.** Evaluation the Agreement of the of blood pressure measured by digital sphygmomanometer compared with Ambulatory blood pressure monitoring. (2023)
- 2.** Investigating the prevalence and interpretation of coronary ectasia risk factors (with and without associated coronary artery stenosis) in patients undergoing angiography at Chamran Heart Hospital in Isfahan during the past 5 years (2016 to 2020). (2023)
- 3.** Evaluation of severity and angiographic patterns of coronary arteries in women with coronary artery disease in Iran. (2022)
- 4.** Evaluation of in-hospital mortality and 6 months later acute myocardial infarction with ST-segment elevation (STEMI) in patients with COVID-19. (2021-2022)
- 5.** Frequency and cost of invasive diagnostic and therapeutic measures for cardiovascular diseases in selected hospitals in Isfahan in 2019-2020. (2021)
- 6.** Comparative study of vascular complications related to arterial sheet extraction using clamp ease and hand pressure in patients undergoing angiography admitted to the Post Angiography ward of Shahid Chamran Hospital in Isfahan in 1400. (2021)
- 7.** Evaluation of the validity of indirect arterial blood pressure measurement methods in comparison with direct intra-aortic blood pressure in patients undergoing coronary angiography. (2021)
- 8.** Evaluation of short-term clinical treatment outcome of patients with ASD Device closure in Chamran heart center, Isfahan, in 2020-2021. (2021)
- 9.** Quality assurance of the National Registry of Angiography and Angioplasty. (2021)
- 10.** Comparison of the efficacy and safety of autologous blood injection with c-clamp vascular closure device in treatment of iatrogenic pseudoaneurysm after femoral artery PUNCTURE. (2021)
- 11.** Long term follows up and clinical outcomes measurement in AAA patients undergoing endo vascular interventions in Isfahan. (2021)
- 12.** Evaluation and one year follow up of Cardiovascular and Non-cardiovascular events in patients undergoing PCI, registered in (2021)
- 13.** A sex specific systematic review and meta-analysis of P2Y12 Inhibitors monotherapy on cardiovascular events and bleeding complications in patients underwent PCI with DES. (2021)
- 14.** The Predictive Value of Calcium Score to Calcium Foci Ratio in determining diagnostic CT angiography and in the severity of Coronary Artery Disease. (2021)
- 15.** Evaluation of the mean of the second and third blood pressure measured in comparison with the first measurement and correlation between the measured values of blood pressure in three times in Isfahan (2020)
- 16.** Comparison of the efficacy and safety of autologous blood injection with c-clamp vascular closure device in treatment of iatrogenic pseudoaneurysm after femoral artery puncture. (2020)
- 17.** Determining the effect of design and implementation of Data quality control process system (DATA REGISTRY) Angiography-angioplasty of coronary arteries on indicators of integrity, stability, comprehensiveness and user friendly of the system. (2020)
- 18.** Short term Cardiovascular event and end organ damage in hypertensive disorder 1397-1399. (2020)

- 19.** The Comparison of Pulmonary Embolism Response Team (PERT) and Conventional Hospital Care in Decreasing Complication Rates of High risk Pulmonary Thromboembolism in 2019, Isfahan, Iran (2019)
- 20.** The study of positive family history of hypertension in people who have hypertension, prehypertension and normal blood pressure (2019)
- 21.** Determining lifestyle risk factors in patients with premature coronary artery disease according to different ethnicities in Iran compared with healthy people and comparing between different ethnicities and establishing a biobank (2019)
- 22.** Determining the outpatient outcome of embryo balloon pump implantation in internal heart patients from 1392 to 1398 in Shahid Chamran Heart Hospital of Isfahan (2019).
- 23.** The safety and feasibility of translunar angiography in the patients with unavailable ipsilateral radial access for coronary angiography and angioplasty (2019)
- 24.** The frequency analysis of the findings of myocardial perfusion imaging (MPI) in based on the result of angiographic results in patients with moderate ischemia in Isfahan (2019)
- 25.** An investigation on the relationship of the Levels of Particulate Matter air pollutants which are Less than 2.5 micrometer in diameter (PM2.5) and the mean blood pressure of patients on the first day of their admission to the Hospitals supervised by "Isfahan university of Medical Sciences" in 2011. (2019).
- 26.** A Historical Cohort Data based registry study on cardiovascular events incidence in patients with LM disease with or without 3VD treated by MFU or PCI or CABG admitted in Cath lab of Chamran & Askariyeh hospitals in Isfahan from Iran. (2019)
- 27.** Evaluation of Variety of antihypertensive drugs and medication adherence and its relation with control of blood pressure in patients with hypertension in Isfahan city in 1394(2018)
- 28.** The use of age-period-cohort model in estimation and predictions incidence and prevalence of ischemic heart disease by sex, age and place of residence in the period 2009-2018. (2018)
- 29.** Trans superficial palmar artery as a new percutaneous access site for coronary angiography versus translunar approach in terms of feasibility and safety. (2018)
- 30.** Assessment of Isfahan General Practitioners' Knowledge and Practice Regarding the Management and Treatment of Hypertension and The Effect of Guideline Training on Knowledge and Practice of General Physicians. (2018)
- 31.** Trans snuffbox as a new access site for coronary angiography and angioplasty versus transradial artery (TRA) approach in terms of feasibility and safety (2018)
- 32.** Comparison of two methods of hemostasis by local pressure with hand and use of Ulnar TR band in angiography via Palmar approach (2018)
- 33.** Comparison of two methods of hemostasis by local pressure with hand and use of TR band in angiography via snuffbox approach (2018)
- 34.** The Effect of a Multifaceted Intervention on Blood Pressure Control and Medication Adherence in Patients with Uncontrolled Hypertension: A Randomized Controlled Clinical Trial. (2018)
- 35.** Study of anatomy of the palmar arches arteries and determining the location of the puncture of the branches on the bases of bone landmark in the selective angiography of the radial and ulnar arteries (2018)

- 36.** Assessing the changes of Troponin, I and T Serum Levels before and after of hemodialysis in End-Stage Renal Disease Patients with ejection fraction over than 50 in Isfahan. (2018)
- 37.** Comparison of ECG findings in patients with refractory temporal lobe epilepsy with a control group of epilepsy patients in clinics Ayatollah Kashani hospital.
- 38.** Carotid Artery Stenting in Isfahan; A six-month follow up. (2017)
- 39.** Which of the components of the metabolic syndrome have a greater effect on mortality, CVA and MI? Hyperglycemia, high blood pressure or both? (2017)
- 40.** Comparing results of Renal artery Doppler between two groups, suffering and not suffering from contrast-induced nephropathy after angiography.
- 41.** Endothelial dysfunction in Lone Atrial Fibrillation Patients. (2017)
- 42.** Trends of determinants on prevalence, awareness, treatment and control hypertension among the adults in Isfahan (2001-2015) and evaluation of the effect of expanded chronic care model on control and treatment and self-care (2016)
- 43.** Body mass index or Microalbuminuria, which one is more important for the prediction and prevention of diastolic dysfunction in non-diabetic hypertensive patients? (2016)
- 44.** The effect of telenursing on blood pressure and body mass index in patients with pre-hypertension discharged from the emergency department affiliated to Isfahan university of medical sciences in 1395. (2016).
- 45.** Evaluation of the effects of patent hemostasis in trans-radial angiography in comparison with classical homeostasis. (2016)
- 46.** Comparison of results and complication of patients whom undergone PCI by bio absorbable and drug eluting stents in Isfahan County during 2015 by one year follow up. (2016)
- 47.** Effect of peer support program on adherence to treatment of hypertension in patients with hypertension refer to the center of Isfahan 2015. (2016)
- 48.** Effects of a life style modification program on knowledge, attitude, practice on hypertensive patients with angioplasty Isfahan Chamran hospital 2014. (2016)
- 49.** The association between adherence to DASH diet in different levels of sodium intake and obesity indices in children and adolescents aged 11-18 years, Isfahan, Iran. (2016)
- 50.** The association between 24hour urinary sodium to potassium and overweight and obesity among Iranian children and adolescents aged 11-18 years. (2016)
- 51.** Role of manual thrombectomy on cardiovascular outcome among patients with total cut off vessel myocardial infarction undergoing primary percutaneous coronary intervention. (2016)
- 52.** The effect of the continuous care model on lifestyle modification and changes in blood pressure in patients with hypertension attending Isfahan Hypertension Center in 2015. (2016)
- 53.** Determination the incidence of late cardiovascular consequences in patients with obstructive sleep apnea that refer to Bamdad clinic in duration of 12 months .(2016)
- 54.** Evaluating the impact of fractional flow reserve-guided percutaneous coronary intervention in intermediate coronary artery lesions on the mode of treatment and their outcomes: An Iranian experience. (2015)
- 55.** Is there any relationship between different phenotypes of metabolic syndrome and cardiovascular event? (2015)

- 56.** Evaluating Factors Associated with Uncontrolled Hypertension: Isfahan Cohort Study. (2014)
- 57.** Survey of short-term outcomes of acute myocardial infarction in young patients and related factors. (2014).
- 58.** Long – term effect of renal artery sympathetic ablation and its complication in patients with treatment resistant hypertension. (2014)
- 59.** Evaluation of patients receiving primary percutaneous coronary intervention for acute myocardial infarction. (2013)
- 60.** Primary Percutaneous Coronary Intervention in Isfahan Province. (2013)
- 61.** Late clinical events of drug eluting versus bare metal stenting; OPCES' ancillary Study. (2013)
- 62.** Designing and implementing an intervention program based on the need for family care's in patients with heart failure: a combined study (2013)
- 63.** validity and reproducibility of food frequency questionnaire for assessment of sodium intake, food group contribution in sodium intake and the association with blood pressure in an Iranian population (2013)
- 64.** association study of function of selenoprotein P and S genes in level of DNA, RNA and protein in the subjects with metabolic syndrome and history of coronary artery disease. (2013)
- 65.** Immediate results and six-month outcomes after percutaneous coronary intervention in a referral heart center in Isfahan, Iran (2011) .
- 66.** Polymorphism analyzes the distribution of P450 2C19 * 2 (alleles responsible for resistance to Clopidogrel) in patients with coronary stents who are Persians. (2011)
- 67.** Determining the relationship between albumin to creatinine ratio and electrocardiographic changes in coding in adult's population of Isfahan (2008).
- 68.** Paraxonase (Pon) Activity in Less Than 40 Years Old Nondiabetic Patients with and Without Significant Coronary Artery Disease. (2008)
- 69.** The Effect of Low-Dose Niacin added to Simvastatin on Lipoprotein Pattern. (2007)
- 70.** Evaluation of the effect of adding low dose immediate release nicotinic acid simvastatin in raising HDL. (2007)
- 71.** Comparison between internal carotid atherosclerotic stenosis and mean serum titer of helicobacter pylori IgG (2007)
- 72.** Deep venous thrombosis genetic risk factors set foot in Iran (2007).
- 73.** Does Lipoprotein (a) level have a predictive value in restenosis after coronary stenting? (2006)
- 74.** The relation between carotid ultrasound changes and seropositivity to chlamydia pneumonia in patients with acute stroke (2005)
- 75.** Comparison of the therapeutic effect of atenolol made by Iran and foreign pharmaceutical companies in patients with hypertension (2005)
- 76.** The survey of relationship between organizational culture and employees job satisfaction in universities research centers at Isfahan in 2004. (2004).
- 77.** Evaluation of HDL performance in people under 40 with CAD compared to healthy individuals (2004)

- 78.** Evaluation of the level theoretical knowledge and skill assessment of nursing staff, interns and assistants of Al-Zahra Medical Center in Isfahan about cardiopulmonary resuscitation in 2003. (2003)

Invited Speaker/Lecture

A: International meeting

1. Khosravi A. " What's New in Cath Lab? " In: Sweet Talk: Cardiometabolic & Endocrinology Forum (2-3 June), Istanbul: Turkiye,2023.
2. Khosravi A. "PCI in complication case" In: 13th Middle East Cardiovascular Disease and 6th Congress of Clinical Cases in Complex Cardiovascular Therapeutics (21-24 October), Shiraz: Iran,2021.
3. Khosravi A. "Diagnosis & Patient evaluation before treatment" In: 13th Middle East Cardiovascular Disease and 6th Congress of Clinical Cases in Complex Cardiovascular Therapeutics (21-24 October), Shiraz: Iran,2021.
4. Khosravi A. "Prevention Hypertension" In: 12th Middle East Cardiovascular Disease and 5th Congress of Clinical Cases in Complex Cardiovascular Therapeutics (12 November), Shiraz: Iran,2020.
5. Khosravi A. "Left Main Percutaneous Coronary Intervention" In: 11th Middle East Cardiovascular Congress and 4th Congress of Clinical cases in complex cardiovascular therapeutics (CCCCT4), (24-26 April), Shiraz: Iran, 2019.
6. Khosravi A. "National implementation of cardiovascular disease registry and the role of PI's in other provinces" In: 11th Middle East Cardiovascular Congress and 4th Congress of Clinical cases in complex cardiovascular therapeutics (CCCCT4), (24-26 April), Shiraz: Iran, 2019.
7. Khosravi A. "Complex Cases" In: 11th Middle East Cardiovascular Congress and 4th Congress of Clinical cases in complex cardiovascular therapeutics (CCCCT4), (24-26 April), Shiraz: Iran, 2019.
8. Khosravi A. "Latest Guidelines of Hypertension Prevention, Diagnosis and Treatment" In: 11th Middle East Cardiovascular Congress and 4th Congress of Clinical cases in complex cardiovascular therapeutics (CCCCT4), (24-26 April), Shiraz: Iran, 2019.
9. Khosravi A. "Ascending aorta thrombosis: a rare cause of simultaneous AMI and upper limb ischemia" In: Euro PCR (21-24 May), Paris: France, 2019
10. Khosravi A. "PCI on Left anterior descending" In: Euro PCR (21-24 May), Paris: France, 2019
11. Khosravi A. "Closing Remarks case 16" In: Iran-Euro CTO meeting, (28 Jul), Mashhad: Iran,2017.
12. Khosravi A. "Review of Developing the Hypertension Guideline in Iran" In: 4th International preventive Congress, (30 Sep-2 Oct), Shiraz: Iran, 2015.
13. Khosravi A. "Definitions, Epidemiology of Hypertension" In: International Congress on Cardiac Emergencies. (ICCE). (19-21 Feb), Bandar Abbas: Iran, 2014.
14. Khosravi A. "Cardiac rehabilitation after non-surgical interventions" In: 1st International Congress Cardiac Rehabilitation from research to practice. (21-23 October), Isfahan: Iran,2014.

- 15.** Khosravi A. "Review of the hypertension status and salt consumption rate in Iran" In: 2nd International Preventive Cardiology Congress (16-18 October), Shiraz: Iran, 2013.
- 16.** Khosravi A. "Blood Pressure Epidemiology" In: The First International Congress on Prevention, Diagnosis & Management of Hypertension. (27-29 Sep), Isfahan: Iran, 2011.
- 17.** Khosravi A. "Salt reduction experience and strategies in Iran" In: the 13th International Symposium on Hypertension and Related Diseases. (November 3-6), Beijing: China, 2011.
- 18.** Khosravi A. "Developing Iranian Guidelines for Hypertension Treatment and Control" In: the 13th International Symposium on Hypertension and Related Diseases. (November 3-6), Beijing: China, 2011.

B: National meeting

- 19.** Khosravi A. "Imaging role in angioplasty with bifurcation" In: Non-surgical invasive interventions in congenital, structural heart disease and treatment of chronic coronary heart disease, (9-11 Oct), Mashhad: Iran, 2019.
- 20.** Khosravi A. "Peripheral Intervention" In: 3rd Congress of Clinical cases in complex cardiovascular therapeutics (CCCCT3), (12-13 April), Shiraz: Iran, 2018.
- 21.** Khosravi A. "Multi Vessel PCI" In: Clinical Cases in Complex Cardiovascular Therapy (CCCCT2). (19-31 April), Shiraz: Iran, 2017.
- 22.** Khosravi A. "Endovascular aneurysm repair (EVAR) and thoracic endovascular aortic/aneurysm repair(TEVAR)" In: Clinical Cases in Complex Cardiovascular Therapy (CCCCT2). (19-31 April), Shiraz: Iran, 2017.
- 23.** Khosravi A. "Successful Stenting of Thoracic Aortic Interruption" In: Clinical Cases in Complex Cardiovascular Therapy (CCCCT2). (19-31 April), Shiraz: Iran, 2017.
- 24.** Khosravi A. "Endovascular aneurysm repair(EVAR) and thoracic endovascular aortic/aneurysm repair(TEAVAR)" In: 1st Congress of Clinical cases in Complex Cardiovascular Therapeutics (CCCCT 1) (2-3 June), Shiraz: Iran, 2016.
- 25.** Khosravi A. "Peripheral Intervention (Iliofemoral and BTK)" In: 1st Congress of Clinical cases in Complex Cardiovascular Therapeutics (CCCCT 1). (2-3 June), Shiraz: Iran, 2016.
- 26.** Khosravi A. "Update on Management of ST-Elevation Myocardial Infarction(STEMI)" In: The First Iranian Congress On Acute Coronary Syndromes (1st ICACS), (20-22 July), Tabriz: Iran, (2016).
- 27.** Khosravi A. "The interventions for lower Extremities Venous Disease symposium" In: First Symposium of peripheral vascular disease working group/Iranian Society of International Cardiology. (Jan.16), Rajaie Hospital, Tehran: Iran, 2014.

Participation/Abstract Presentation in Congresses, Seminars, Conferences:

A. International

1. Khosravi A. Euro PCR. (16-19 May), Paris: France, 2023.
2. Khosravi A. TOBI (Total Occlusion and Bifurcation Interventions) Congress (15-17 November), Milano: Italia, 2023.
3. Khosravi A. CTO ESSENTIALS, 14th Chronic Total Occlusion Course (19-21 October), Istanbul: Turkiye, 2023.

4. Khosravi A. 23th International Congress on Cardiovascular Updates(ICCU), (19-22 September), Tehran: Iran,2023.
5. Khosravi A. Gulf PCR. (14-15 Dec), Dubai, United Arab Emirates, 2022.
6. Khosravi A. Euro PCR. (17-20 May), Paris: France, 2022.
7. Khosravi A. Gulf PCR. (15-16 Dec), Dubai, United Arab Emirates, 2021.
8. Khosravi A. Euro PCR. (18-20 May), Paris: France, 2021.
9. Khosravi A. Euro PCR. (21-24 May), Paris: France, 2019.
10. Khosravi A. Euro PCR. (22-25 May), Paris: France, 2018.
11. Khosravi A.7th Cardiovascular Updates Regional Event, (23rd of November), Park INN by Radisson Amsterdam City West .Netherlands, 2018.
12. Khosravi A. "Hyperlipidemia management in healthy population" In: 8th Kowsar Hospital Congress. A decade updates in cardiovascular disease. (April 24-27), shiraz: Iran, 2018. (**Poster Presentation**)
13. Khosravi A. EURO CTO CLUB-9th Experts" Live" Workshop (15-16 September), Berlin: Germany, 2017.
14. Khosravi A. Euro PCR. (16-19 May), Paris: France, 2017.
15. Khosravi A. Leipzig Interventional Course (LINC). (January 24-27), Leipzig: Germany, 2017.
16. Khosravi A. 10th International Cardiology Seminar Focus on Complications. (Jan), Rajaie Cardiovascular Medical & Research Center, Tehran: Iran,2017.
17. Khosravi A. 7th Kowsar Hospital Congress. A decade updates in cardiovascular disease. (April 26-29), shiraz: Iran, 2016.
18. Khosravi A. Euro PCR. (17-20 May), Paris: France,2016.
19. Khosravi A. Leipzig Interventional Course (LINC). (January 26-29), Leipzig: Germany, 2016.
20. Khosravi A.ESC Congress. (27-31 August), Rome: Italy, 2016.
21. Khosravi A, et al. "Validation of spot urine sample compared to 24hours urine collection as a biomarker for assessment of sodium intake: Isfahan salt study" In: Word Congress of Cardiology & Cardiovascular Health(WCC), (4-7June), Mexico City: Mexico, 2016. (**Abstract**)
22. Khosravi A. Merck Serono Middle East Fz-LLC. (26-28 November), Budapest: Hungary,2015.
23. Khosravi A. The 16th CTO Club. (19-20 Jun), Nagoya: Japan,2015.
24. Khosravi A. Euro PCR. (19-22 May), Paris: France,2015.
25. Khosravi A. "Iranian Network of Cardiovascular Research" In: 4th International preventive Congress, (30 Sep-2 Oct), Shiraz: Iran, 2015.
26. Khosravi A. 4th International preventive Congress, (30 Sep-2 Oct), Shiraz: Iran, 2015
27. Khosravi A, et al. "Evaluating Factors Associated with Uncontrolled Hypertension: Isfahan Cohort Study" In: 1st International Congress Cardiac Rehabilitation from research to practice. (21-23 October), Isfahan: Iran,2014. (**Poster Presentation**)
28. Khosravi A. Esc Congress, (30Aug- 3 Sep), Barcelona: Spain, 2014.
29. Khosravi A, et al. "Comparison opinions about causes of failure medication adherence in hypertension" In: 1st International Congress Cardiac Rehabilitation from research to practice. (21-23 October), Isfahan: Iran,2014. (**Poster Presentation**)

30. Khosravi A, et al. "Perspective of hospital incidence rate of deep venous coagulopathy" In: 1st International Congress Cardiac Rehabilitation from research to practice. (21-23 October), Isfahan: Iran,2014. (**Poster Presentation**)
31. Khosravi A, et al. "A case of Marfan's syndrome with multi-level aortic dissections" In: 1st International Congress Cardiac Rehabilitation from research to practice. (21-23 October), Isfahan: Iran,2014. (**Poster Presentation**)
32. Khosravi A. Leipzig Interventional Course (LINC). (January 28-31), Leipzig: Germany, 2014. (**Abstract**)
33. Khosravi A. Euro PCR, (20-23 May), Paris: France, 2014.
34. Khosravi A. Euro PCR, (21-24 May), Paris: France, 2013.
35. Khosravi A. The role of community-based lifestyle intervention on salt intake and blood pressure in Iran. ESC congress, (26 August), Munich: Germany, 2012. (**Poster Presentation**)
36. Khosravi A. Hypertension control in industrial impact of shimsco study in Iran. ESC congress, (27 August), Munich: Germany, 2012. (**Poster Presentation**)
37. Khosravi A. "Treatment choice in hypertension: evidence versus conventional opinion", (August 25), Munich: Germany,2012.
38. Khosravi A. Total Occlusion and Bifurcation Interventions Congress. (September 15-16), Venice Mestre: Italia, 2011.
39. Khosravi A, et al. "Prevalence, treatment and awareness of Hypertension and its care in Isfahan " In: The First International Congress on Prevention, Diagnosis & Management of Hypertension. (27-29 Sep), Isfahan: Iran,2011. (**Oral Presentation**)
40. Khosravi A, et al. "Comparison of three methods of hope therapy, drug therapy and cognitive-behavioral therapy on the general health of patients with major hypertension" In: The First International Congress on Prevention, Diagnosis & Management of Hypertension. (27-29 Sep), Isfahan: Iran,2011. (**Oral Presentation**)
41. Khosravi A, et al. "Pulmonary artery Pressure and cardiac output effects of the arteriovenous fistula in patients with chronic renal failure" In: The First International Congress on Prevention, Diagnosis & Management of Hypertension. (27-29 Sep), Isfahan: Iran,2011. (**Poster Presentation**)
42. Khosravi A, et al. " Comparison of weight indicators and heart risk factors by gender in a sample group of Isfahan urban society" In: The First International Congress on Prevention, Diagnosis & Management of Hypertension. (27-29 Sep), Isfahan: Iran,2011 (**Poster Presentation**)
43. Khosravi A, et al. " Is there the relation between Microalbuminuria and cardiovascular risk factors in Iranian General Population?" In: The First International Congress on Prevention, Diagnosis & Management of Hypertension. (27-29 Sep), Isfahan: Iran,2011 (**Poster Presentation**)
44. Khosravi A, et al. " Worksite Action Plan for Controlling Hypertension in industrial Employers" In: The First International Congress on Prevention, Diagnosis & Management of Hypertension. (27-29 Sep), Isfahan: Iran,2011. (**Oral Presentation**)
45. Khosravi A, et al. " Assessment of medical treatment of hypertension in Isfahan, Najafabad and Arak" In: The First International Congress on Prevention, Diagnosis & Management of Hypertension. (27-29 Sep), Isfahan: Iran,2011 (**Poster Presentation**)

46. Khosravi A. Euro PCR. (17-20 May), Paris: France,2011.
47. Khosravi A. 3th International Psychosomatic Congress. (25-27 May), Isfahan University of Medical Sciences, Isfahan: Iran,2011.
48. Boroujeni F,Zamania b,Wirza R,Maskon O,**Khosravi A**, Khalilian M. An improved seed point detection algorithm for centerline tracing in coronary angiograms. In: 7th International Conference on Information Technology - New Generations, ITNG 201012 April 2010through 14 April 2010. Code 81329. Pages 352 - 3572010 Article number 5501703.
49. Khosravi A. Euro PCR. (25-28 May), Paris: France,2010.
50. Khosravi A. "Preprocedural C-Reactive Protein Predictive Value in Angiographic instant Restenosis after Coronary Stent Placement in Patients with Stable Angina "In: International Symposium on Atherosclerosis. (14-18 June), Boston, Massachusetts: USA,2009. (**Abstract**)
51. Khosravi A. Euro PCR. (25-28 May), Paris: France,2004.

B. National

52. Khosravi A.8th Iranian Joint Cardiovascular Congress (14-16 June), Rajaie Conference Center, Tehran: Iran,2023.
53. Khosravi A. Joint Iranian Cardiovascular Program. Shahid Rajaie Cardiovascular Research, Treatment and Training Center, (27Feb-1March) Tehran: Iran, 2019.
54. Khosravi A. Iran CTO & Bifurcation Meeting (5-6 Dec), Razavi Hospital Mashhad: Iran,2018.
55. Khosravi A. Cardiovascular Congress. (29Nov-1Dec), Tehran University of Medical Sciences: Iran, 2017.
56. Khosravi A. 4th Iranian Cardiovascular Joint Congress. (1-4 March), Tehran: Iran, (2016)
57. National Workshop on Cardiovascular Diseases. (7Jan), Isfahan University of Medical Sciences, Isfahan: Iran,2016.
58. Khosravi A. "Health Evidence Synthesis and Guideline Development using the Grade Approach" In: Isfahan University of Medical Sciences, (14-15 Dec), Isfahan: Iran,2016.
59. Khosravi A. 17th Congress of Iranian Heart Association. (10-13 May0, Tehran: Iran, 2011.
60. Khosravi A. The second annual Conference on Interventional Cardiology. (5-6 Feb), Shaheed Rajaie Heart center, Tehran: Iran,2009.
61. Khosravi A. The First Regional (EMRO) Congress on Tobacco and Health, CAD morbidity in diabetic and non- diabetic group in smoker, passive smoke and non-smoker. (28-30 Jan), Kish Island: Iran, 2009.
62. Khosravi A. Conference on Heart and New Technologies. (28Feb-3March), Mazandaran University of Medical Sciences: Iran,2006.
63. Khosravi A. 6th National Congress of Cardiology. (11-12 June), Mashhad: Iran, 2004.